

1

Assessment and Pathophysiology



References

1.1 Obtain a Weight History

1. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obesity Pillars*. 2022;1:100004. doi:10.1016/j.obpill.2021.100004
2. Han SJ, Lee SH. Nontraditional Risk Factors for Obesity in Modern Society. *J Obes Metab Syndr*. 2021;30(2):93-103. doi:10.7570/jomes21004
3. Singh A, Hardin BI, Keyes D. Epidemiologic and Etiologic Considerations of Obesity. In: *StatPearls*. StatPearls Publishing; 2025. Accessed October 20, 2025. <http://www.ncbi.nlm.nih.gov/books/NBK585067/>
4. van der Valk ES, van den Akker ELT, Savas M, et al. A comprehensive diagnostic approach to detect underlying causes of obesity in adults. *Obes Rev*. 2019;20(6):795-804. doi:10.1111/obr.12836
5. *Factors Affecting Weight & Health - NIDDK*. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed October 20, 2025. <https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/factors-affecting-weight-health>
6. Bays HE, Golden A, Tondt J. Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obesity Pillars*. 2022;3:100034. doi:10.1016/j.obpill.2022.100034
7. Casazza K, Fontaine KR, Astrup A, et al. Myths, Presumptions, and Facts about Obesity. *N Engl J Med*. 2013;368(5):446-454. doi:10.1056/NEJMsa1208051
8. Casazza K, Brown A, Astrup A, et al. Weighing the Evidence of Common Beliefs in Obesity Research. *Critical Reviews in Food Science and Nutrition*. 2015;55(14):2014-2053. doi:10.1080/10408398.2014.922044

1.2 Obtain a Neuropsychiatric History

1. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. *World J Diabetes*. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390
2. McElroy SL, Keck PE Jr. Obesity in bipolar disorder: an overview. *Curr Psychiatry Rep*. 2012;14(6):650-658. doi:10.1007/s11920-012-0313-8
3. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. *Arch Gen Psychiatry*. 2006;63(7):824-830. doi:10.1001/archpsyc.63.7.824
4. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry*. 2010;67(3):220-229. doi:10.1001/archgenpsychiatry.2010.2
5. Newcomer JW. Metabolic syndrome and mental illness. *Am J Manag Care*. 2007;13(7 Suppl):S170-S177.
6. Adam TC, Epel ES. Stress, eating and the reward system. *Physiol Behav*. 2007;91(4):449-458. doi:10.1016/j.physbeh.2007.04.011
7. Friedman KE, Reichmann SK, Costanzo PR, et al. Body Image Partially Mediates the Relationship between Obesity and Psychological Distress. *Obesity Res*. 2002;10(1):33-41. doi.org/10.1038/oby.2002.5
8. Berthoud HR, Münzberg H, Richards BK, Morrison CD. Neural and metabolic regulation of macronutrient intake and selection. *Proc Nutr Soc*. 2012;71(3):390-400. doi:10.1017/S0029665112000559
9. Vgontzas AN, Kales A. Sleep and its disorders. *Annu Rev Med*. 1999;50:387-400. doi:10.1146/annurev.med.50.1.387
10. Marek RJ, Ben-Porath YS, Heinberg LJ. Understanding the role of psychopathology in bariatric surgery outcomes. *Obesity Reviews*. 2016;17(2):126-141. doi:10.1111/obr.12356
11. Miller, WR, Rollnick S. *Motivational Interviewing: Helping People Change*. 4th ed. Guilford Press; 2023.
12. Berthoud HR, Lenard NR, Shin AC. Food reward, hyperphagia, and obesity. *Am J Physiol Regul Integr Comp Physiol*. 2011;300(6):R1266-R1277. doi:10.1152/ajpregu.00028.2011
13. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. *Nature*. 2006;443(7109):289-295. doi:10.1038/nature05026
14. Volkow ND, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. *Trends Cogn Sci*. 2011;15(1):37-46. doi:10.1016/j.tics.2010.11.001
15. Batterink L, Yokum S, Stice E. Body mass correlates inversely with inhibitory control in response to food among adolescent girls: an fMRI study. *Neuroimage*. 2010;52(4):1696-1703. doi:10.1016/j.neuroimage.2010.05.059
16. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nat Rev Neurosci*. 2012;13(10):701-712. doi:10.1038/nrn3346
17. Adam TC, Epel ES. Stress, eating and the reward system. *Physiol Behav*. 2007;91(4):449-458. doi:10.1016/j.physbeh.2007.04.011
18. Kullmann S, Kleinridders A, Small DM, et al. Central nervous pathways of insulin action in the control of metabolism and food intake. *Lancet Diabetes Endocrinol*. 2020;8(6):524-534. doi:10.1016/S2213-8587(20)30113-3
19. Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med*. 2004;1(3):e62. doi:10.1371/journal.pmed.0010062

1.3 Obtain a Social History & Identify Social Determinants of Health

1. Kumar R, Rizvi MR, Saraswat S. Obesity and Stress: A Contingent Paralysis. *Int J Prev Med.* 2022 Jun 24;13:95. doi: 10.4103/ijpvm.IJPVM_427_20. PMID: 35958362; PMCID: PMC9362746.
2. Chiolero, A., Jacot-Sadowski, I., Faeh, D., Paccaud, F., & Cornuz, J. (2007). Association of cigarettes smoked daily with obesity in a general adult population. *Obesity, 15(5), 1311-1318.*
3. Sayon-Orea, C., Martinez-Gonzalez, M. A., & Bes-Rastrollo, M. (2011). Alcohol consumption and body weight: A systematic review. *Nutrition Reviews, 69(8), 419-431.* This review examines the effects of alcohol consumption on body weight.
4. Le Strat, Y., Ducroz, L., Watzke, A. B., Le Foll, B., & Dubertret, C. (2011). Marijuana and body mass index: A meta-analysis of two representative national surveys. *Journal of Addictive Medicine, 5(1), 17-26.*
5. Gearhardt, A. N., Corbin, W. R., & Fromme, K. (2011). The relationship between marijuana use and body mass index in a national sample of college students. *Addictive Behaviors, 36(3), 277-281*
6. Reis MG, Ferreira AJF, Sohoulí MH, Taimeirão DR, Vieira RAL, Guimarães NS. Effect of cannabis and subproducts on anthropometric measures: a systematic review and meta-analysis. *Int J Obes (Lond).* 2024 Jan;48(1):44-54. doi: 10.1038/s41366-023-01399-x. Epub 2023 Nov 7. PMID: 37935909.
7. Niebylski, M. L., Redburn, K. A., Duhaney, T., & Campbell, N. R. (2015). Healthy food subsidies and unhealthy food taxation: A systematic review of the evidence. *Nutrition, 31(6), 787-795.*
8. Christakis, N. A., & Fowler, J. H. (2007). The spread of obesity in a large social network over 32 years. *New England Journal of Medicine, 357, 370-379*
9. Church, T. S., Thomas, D. M., Tudor-Locke, C., Katzmarzyk, P. T., Earnest, C. P., Rodarte, R. Q., ... & Bouchard, C. (2011). Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. *PLoS One, 6(5), e19657.*
10. Landsbergis, P. A., Schnall, P. L., Belkic, K. L., Baker, D., Schwartz, J., & Pickering, T. G. (2013). Work stressors and cardiovascular disease. *Work.*
11. Church, T. S., Thomas, D. M., Tudor-Locke, C., Katzmarzyk, P. T., Earnest, C. P., Rodarte, R. Q., ... & Bouchard, C. (2011). Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. *PLoS One, 6(5), e19657.*
12. Landsbergis, P. A., Schnall, P. L., Belkic, K. L., Baker, D., Schwartz, J., & Pickering, T. G. (2013). Work stressors and cardiovascular disease. *Work.*
13. Jeffery, R. W., & Rick, A. M. (2002). Cross-sectional and longitudinal associations between body mass index and marriage-related factors. *Obesity Research, 10(8), 809-815.*
14. Sobal, J., Rauschenbach, B., & Frongillo, E. A. Jr. (2003). Marital status changes and body weight changes: a US longitudinal analysis. *Social Science & Medicine, 56(7), 1543-1555.*
15. Conklin, A. I., Maguire, E. R., & Monsivais, P. (2014). Economic determinants of diet in older adults: systematic review. *Journal of Epidemiology and Community Health, 68(8), 769-775.*
16. Rosenbaum, A., & Langhinrichsen-Rohling, J. (2006). Meta-research on violence and victims: *Aggression and Violent Behavior, 11(5), 473-488.*
17. Felitti, V. J., Anda, R. F., Nordenberg, D., Williamson, D. F., Spitz, A. M., Edwards, V., ... & Marks, J. S. (1998). Experiences (ACE) Study. *American Journal of Preventive Medicine, 14(4), 245-258.*
18. Popkin, B. M. (2001). The nutrition transition and obesity in the developing world. *Journal of Nutrition, 131(3), 871S-873S*

19. Drewnowski, A., & Specter, S. E. (2004). Poverty and obesity: The role of energy density and energy costs. *American Journal of Clinical Nutrition*, 79(1), 6-16.
20. Cutler, D. M., & Lleras-Muney, A. (2006). Education and health: Evaluating theories and evidence. National Bureau of Economic Research (Working Paper No. 12352). This paper covers how education affects health outcomes, including obesity.
21. Sallis, J. F., Floyd, M. F., Rodríguez, D. A., & Saelens, B. E. (2012). Role of built environments in physical activity, obesity, and cardiovascular disease. *Circulation*, 125(5), 729-737. The article reviews how physical environments influence activity levels and obesity.
22. Thornton, R. L., Glover, C. M., Cené, C. W., Glik, D. C., Henderson, J. A., & Williams, D. R. (2016). Evaluating strategies for reducing health disparities by addressing the social determinants of health. *Health Affairs*, 35(8), 1416-1423. This provides insight into how healthcare access impacts health disparities, including obesity.
23. Harris, J. L., Pomeranz, J. L., Lobstein, T., & Brownell, K. D. (2009). A crisis in the marketplace: How food marketing contributes to childhood obesity and what can be done. *Annual Review of Public Health*, 30, 211-225.
24. Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011). The global obesity pandemic: Shaped by global drivers and local environments. *The Lancet*, 378(9793), 804-814. This discusses policy interventions to address the obesity epidemic.
25. Cultural and Social Norms: Brown, P. J., & Konner, M. (1987). An anthropological perspective on obesity. *Annals of the New York Academy of Sciences*, 499, 29-46.
26. Gender identity: Calzo, J.P., et al. (2017)

1.4 Obtain a History of Weight Related Metabolic & Biomechanical Complications

1. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J Med*. 2014;371(12):1131-1141. doi:10.1056/NEJMra1011035
2. Longo M, Zatterale F, Naderi J, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. *Int J Mol Sci*. 2019;20(9):2358. Published 2019 May 13. doi:10.3390/ijms20092358
3. Engin A. Adipose Tissue Hypoxia in Obesity: Clinical Reappraisal of Hypoxia Hypothesis. *Adv Exp Med Biol*. 2024;1460:329-356. doi:10.1007/978-3-031-63657-8_11
4. Molina-Garcia P, Migueles JH, Cadenas-Sanchez C, et al. A systematic review on biomechanical characteristics of walking in children and adolescents with overweight/obesity: Possible implications for the development of musculoskeletal disorders. *Obes Rev*. 2019;20(7):1033-1044. doi:10.1111/obr.12848
5. Runhaar J, Koes BW, Clockaerts S, Bierma-Zeinstra SM. A systematic review on changed biomechanics of lower extremities in obese individuals: a possible role in development of osteoarthritis. *Obes Rev*. 2011;12(12):1071-1082. doi:10.1111/j.1467-789X.2011.00916.x
6. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *J Clin Lipidol*. 2024;18(3):e320-e350. doi:10.1016/j.jacl.2024.04.001
7. Pedersen SD. Metabolic complications of obesity. *Best Pract Res Clin Endocrinol Metab*. 2013;27(2):179-193. doi:10.1016/j.beem.2013.02.004
8. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238

9. Wilding JPH. Endocrine testing in obesity. *Eur J Endocrinol*. 2020;182(4):C13-C15. doi:10.1530/EJE-20-0099
10. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics*. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
11. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. *Obesity (Silver Spring)*. 2014;22 Suppl 2:S5-S39. doi:10.1002/oby.20821
12. Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzone KA, Jay M. Obesity Management in Adults: A Review. *JAMA*. 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897
13. Garvey WT, Mechanick JI, Brett EM, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. *Endocr Pract*. 2016;22 Suppl 3:1-203. doi:10.4158/EP161365.GL
14. Kushner RF, Batsis JA, Butsch WS, et al. Weight History in Clinical Practice: The State of the Science and Future Directions. *Obesity (Silver Spring)*. 2020;28(1):9-17. doi:10.1002/oby.22642

1.5 Diagnose Weight-Related Metabolic & Biomechanical Complications

1. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;326(8):736-743. doi:10.1001/jama.2021.12531
2. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *J Clin Lipidol*. 2024;18(3):e320-e350. doi:10.1016/j.jacl.2024.04.001
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;73(24):3168-3209. doi:10.1016/j.jacc.2018.11.002
4. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140(11):e563-e595. doi:10.1161/CIR.0000000000000677
5. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2022;328(8):746. doi:10.1001/jama.2022.13044
6. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. *J Clin Lipidol*. 2024;18(5):e647-e663. doi:10.1016/j.jacl.2024.08.013
7. Wong ND, Fan W, Hu X, et al. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. *J Am Coll Cardiol*. 2024;83(16):1511-1525. doi:10.1016/j.jacc.2024.02.031
8. Ulloque-Badaracco JR, Al-Kassab-Córdova A, Hernandez-Bustamante EA, et al. Association of

apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis. *Lipids Health Dis.* 2023;22(1):98. Published 2023 Jul 7. doi:10.1186/s12944-023-01860-w

9. American Diabetes Association Professional Practice Committee. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2025. *Diabetes Care.* 2025;48(1 Suppl 1):S14-S26. doi:10.2337/dc25-S001
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA.* 2001;285(19):2486-2497. doi:10.1001/jama.285.19.2486
11. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation.* 2005;112(17):2735-2752. doi:10.1161/CIRCULATIONAHA.105.169404
12. Simental-Mendía LE, Guerrero-Romero F. The correct formula for the triglycerides and glucose index. *Eur J Pediatr.* 2020;179(7):1171. doi:10.1007/s00431-020-03644-1
13. Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. *Prev Med.* 2014;62:96-102. doi:10.1016/j.ypmed.2014.02.003
14. Stovitz SD, Banack HR, Kaufman JS. Structural Bias in Studies of Cardiovascular Disease: Let's Not Be Fooled by the "Obesity Paradox". *Can J Cardiol.* 2018;34(5):540-542. doi:10.1016/j.cjca.2017.10.025
15. Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease?. *Ann Epidemiol.* 2015;25(5):342-349. doi:10.1016/j.annepidem.2015.02.008

1.6 Diagnose Secondary Causes of Weight Gain or Obesity

1. Biondi B. Thyroid and obesity: an intriguing relationship. *J Clin Endocrinol Metab.* 2010;95(8):3614-3617. doi:10.1210/jc.2010-1245
2. van der Valk ES, van den Akker ELT, Savas M, et al. A comprehensive diagnostic approach to detect underlying causes of obesity in adults. *Obes Rev.* 2019;20(6):795-804. doi:10.1111/obr.12836
3. Barber TM, Franks S. Obesity and polycystic ovary syndrome. *Clinical Endocrinology.* 2021;95(4):531-541. doi:10.1111/cen.14421
4. Armeni E. Male hypogonadism in overweight and obesity. *mtod.* 2023;3(2):N/A-N/A. doi:10.20517/mtod.2023.05
5. De Lorenzo A, Noce A, Moriconi E, et al. MOSH Syndrome (Male Obesity Secondary Hypogonadism): Clinical Assessment and Possible Therapeutic Approaches. *Nutrients.* 2018;10(4):474. doi:10.3390/nu10040474
6. Fernandez CJ, Chacko EC, Pappachan JM. Male Obesity-related Secondary Hypogonadism – Pathophysiology, Clinical Implications and Management. *Eur Endocrinol.* 2019;15(2):83-90. doi:10.17925/EE.2019.15.2.83
7. NCHS Data Brief, Number 360, February 2020. Accessed May 4, 2025. <https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf>
8. Knight MG, Anekwe C, Washington K, Akam EY, Wang E, Stanford FC. Weight regulation in menopause. *Menopause.* 2021;28(8):960-965. doi:10.1097/GME.0000000000001792
9. Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. *Menopause.* 2024;31(4):266-274. doi:10.1097/GME.0000000000002310

10. Park HK, Ahima RS. Endocrine disorders associated with obesity. *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2023;90:102394. doi:10.1016/j.bpobgyn.2023.102394
11. Hypothalamic obesity: from basic mechanisms to clinical perspectives - *ClinicalKey*. Accessed May 3, 2025. <https://www-clinicalkey-com.wrnmmc.idm.oclc.org/#!/content/playContent/1-s2.0-S2213858724002833?returnurl=null&referrer=null>
12. Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. *J Endocrinol Invest*. 2019;42(1):61-73. doi:10.1007/s40618-018-0887-z
13. Herbst KL, Kahn LA, Iker E, et al. Standard of care for lipedema in the United States. *Phlebology*. 2021;36(10):779-796. doi:10.1177/02683555211015887
14. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2015;100(2):363-370. doi:10.1210/jc.2014-3421
15. Leslie WS, Hankey CR, Lean MEJ. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. *QJM*. 2007;100(7):395-404. doi:10.1093/qjmed/hcm044
16. Beccuti G, Pannain S. Sleep and obesity. *Curr Opin Clin Nutr Metab Care*. 2011;14(4):402-412. doi:10.1097/MCO.0b013e3283479109
17. Ford ES, Li C, Wheaton AG, Chapman DP, Perry GS, Croft JB. Sleep duration and body mass index and waist circumference among U.S. adults. *Obesity (Silver Spring)*. 2014;22(2):598-607. doi:10.1002/oby.20558
18. Tasali E, Wroblewski K, Kahn E, Kilkus J, Schoeller DA. Effect of Sleep Extension on Objectively Assessed Energy Intake Among Adults With Overweight in Real-life Settings: A Randomized Clinical Trial. *JAMA Intern Med*. 2022;182(4):365-374. doi:10.1001/jamainternmed.2021.8098

1.7 Diagnose Genetic or Syndromic Causes of Obesity

1. Mason K, Page L, Balikcioglu PG. Screening for hormonal, monogenic, and syndromic disorders in obese infants and children. *Pediatr Ann*. 2014;43(9):e218-e224. doi:10.3928/00904481-20140825-08
2. Mahmoud R, Kimonis V, Butler MG. Genetics of Obesity in Humans: A Clinical Review. *Int J Mol Sci*. 2022;23(19):11005. Published 2022 Sep 20. doi:10.3390/ijms231911005
3. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. *Nat Rev Genet*. 2022;23(2):120-133. doi:10.1038/s41576-021-00414-z
4. Argente J, Rosenberg A, Rodeberg D, Stumpf J, Baver S, Segal S. Clinical characteristics of human POMC, PCSK1, and LEPR deficiencies. In: *Endocrine Abstracts*. Vol 63. Bioscientifica; 2019. doi:10.1530/endoabs.63.P976
5. Huvenne H, Dubern B, Clément K, Poitou C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. *Obes Facts*. 2016;9(3):158-173. doi:10.1159/000445061
6. Ayers KL, Glicksberg BS, Garfield AS, et al. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. *J Clin Endocrinol Metab*. 2018 Jul 1;103(7):2601-2612. doi: 10.1210/jc.2018-00258.

1.8 Diagnose Obesity & Characterize Its Severity

1. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. *The Lancet Diabetes & Endocrinology*. 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4
2. Bray GA. Beyond BMI. *Nutrients*. 2023;15(10):2254. doi:10.3390/nu15102254
3. Nevill AM, Duncan MJ, Myers T. BMI is dead; long live waist-circumference indices: But which index should we choose to predict cardio-metabolic risk? *Nutrition, Metabolism and Cardiovascular Diseases*. 2022;32(7):1642-1650. doi:10.1016/j.numecd.2022.04.003
4. Chirinos DA, Llabre MM, Goldberg R, et al. Defining Abdominal Obesity as a Risk Factor for Coronary Heart Disease in the US: Results From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *Diabetes Care*. 2020;43(8):1774-1780. doi:10.2337/dc19-1855
5. Gibson S, Ashwell M. A simple cut-off for waist-to-height ratio (0.5) can act as an indicator for cardiometabolic risk: recent data from adults in the Health Survey for England. *Br J Nutr*. 2020;123(6):681-690. doi:10.1017/S0007114519003301
6. Nevill AM, Leahy GD, Mayhew J, Sandercock GRH, Myers T, Duncan MJ. 'At risk' waist-to-height ratio cut-off points recently adopted by NICE and US Department of Defense will unfairly penalize shorter adults. What is the solution? *Obesity Research & Clinical Practice*. 2023;17(1):1-8. doi:10.1016/j.orcp.2023.01.002
7. Waist circumference and waist-hip ratio: report of a WHO expert consultation. Accessed October 4, 2025. <https://www.who.int/publications/i/item/9789241501491>
8. Kornej J, Lin H, Trinquart L, et al. Neck Circumference and Risk of Incident Atrial Fibrillation in the Framingham Heart Study. *Journal of the American Heart Association*. Published online February 15, 2022. doi:10.1161/JAHA.121.022340
9. Preis SR, Massaro JM, Hoffmann U, et al. Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. *J Clin Endocrinol Metab*. 2010;95(8):3701-3710. doi:10.1210/jc.2009-1779
10. Pennings N, Golden L, Yashi K, Tondt J, Bays HE. Sleep-disordered breathing, sleep apnea, and other obesity-related sleep disorders: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;4:100043. Published 2022 Nov 15. doi:10.1016/j.obpill.2022.100043
11. Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. *CMAJ*. 2011;183(14):E1059-E1066. doi:10.1503/cmaj.110387
12. Atlantis E, Sahebolamri M, Cheema BS, Williams K. Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: A rapid review of observational studies. *Obesity Reviews*. 2020;21(11):e13120. doi:10.1111/obr.13120
13. Stephenson J, Smith CM, Kearns B, Haywood A, Bissell P. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. *BMC Public Health*. 2021;21(1):1990. doi:10.1186/s12889-021-12009-8
14. Taylor VH, Forhan M, Vigod SN, McIntyre RS, Morrison KM. The impact of obesity on quality of life. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2013;27(2):139-146. doi:10.1016/j.beem.2013.04.004
15. The Utility of Body Composition Assessment in Nutrition and Clinical Practice: An Overview of Current Methodology. Accessed October 5, 2025. <https://www.mdpi.com/2072-6643/13/8/2493>
16. Heymsfield SB, Ebbeling CB, Zheng J, et al. Multi-component molecular-level body composition reference methods: evolving concepts and future directions. *Obesity Reviews*. 2015;16(4):282-294. doi:10.1111/obr.12261

17. Son JW, Han BD, Bennett JP, Heymsfield S, Lim S. Development and clinical application of bioelectrical impedance analysis method for body composition assessment. *Obesity Reviews*. 2025;26(1):e13844. doi:10.1111/obr.13844
18. BurrIDGE K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;1:100007. Published 2022 Jan 10. doi:10.1016/j.obpill.2021.100007
19. Macena M de L, Paula DT da C, da Silva Júnior AE, et al. Estimates of resting energy expenditure and total energy expenditure using predictive equations in adults with overweight and obesity: a systematic review with meta-analysis. *Nutr Rev*. 2022;80(11):2113-2135. doi:10.1093/nutrit/nuac031
20. Calcagno M, Kahleova H, Alwarith J, et al. The Thermic Effect of Food: A Review. *Journal of the American College of Nutrition*. 2019;38(6):547-551. doi:10.1080/07315724.2018.1552544
21. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. *Front Endocrinol*. 2016;7. doi:10.3389/fendo.2016.00030
22. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. *The Lancet Diabetes & Endocrinology*. 2019;7(9):715-725. doi:10.1016/S2213-8587(19)30084-1
23. Mallick R, Basak S, Das RK, et al. Fatty Acids and their Proteins in Adipose Tissue Inflammation. *Cell Biochem Biophys*. 2024;82(1):35-51. doi:10.1007/s12013-023-01185-6
24. Ye RZ, Richard G, Gévry N, Tchernof A, Carpentier AC. Fat Cell Size: Measurement Methods, Pathophysiological Origins, and Relationships With Metabolic Dysregulations. *Endocr Rev*. 2022;43(1):35-60. doi:10.1210/endrev/bnab018
25. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. *Int J Obes (Lond)*. 2010;34 Suppl 1(0 1):S47-S55. doi:10.1038/ijo.2010.184
26. Aronne LJ, Hall KD, M. Jakicic J, et al. Describing the Weight-Reduced State: Physiology, Behavior, and Interventions. *Obesity*. 2021;29(S1):S9-S24. doi:10.1002/oby.23086
27. Müller MJ, Heymsfield SB, Bosy-Westphal A. Changes in body composition and homeostatic control of resting energy expenditure during dietary weight loss. *Obesity (Silver Spring)*. 2023;31(4):892-895. doi:10.1002/oby.23703 C


1.9 Discuss Obesity as a Complex Chronic Disease

1. Telles Correia D, Stoyanov D, Rocha Neto HG. How to define today a medical disorder? Biological and psychosocial disadvantages as the paramount criteria. *J Eval Clin Pract.* 2022;28(6):1195-1204. doi:10.1111/jep.13592
2. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics.* 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
3. Lowell BB. New Neuroscience of Homeostasis and Drives for Food, Water, and Salt. *N Engl J Med.* 2019;380(5):459-471. doi:10.1056/NEJMra1812053
4. Arcon M. The interplay between hypothalamic and brainstem nuclei in homeostatic control of energy balance. *Behav Brain Res.* 2025;480:115398. doi:10.1016/j.bbr.2024.115398
5. Fasano A. The Physiology of Hunger. *N Engl J Med.* 2025;392(4):372-381. doi:10.1056/NEJMra2402679
6. Melby CL, Paris HL, Foright RM, Peth J. Attenuating the Biologic Drive for Weight Regain Following Weight Loss: Must What Goes Down Always Go Back Up?. *Nutrients.* 2017;9(5):468. Published 2017 May 6. doi:10.3390/nu9050468
7. Martins C, Roekenes JA, Rehfeld JF, Hunter GR, Gower BA. Metabolic adaptation is associated with a greater increase in appetite following weight loss: a longitudinal study. *Am J Clin Nutr.* 2023;118(6):1192-1201. doi:10.1016/j.ajcnut.2023.10.010
8. Speakman JR, Hall KD. Models of body weight and fatness regulation. *Philos Trans R Soc Lond B Biol Sci.* 2023;378(1888):20220231. doi:10.1098/rstb.2022.0231
9. Jéquier E, Tappy L. Regulation of body weight in humans. *Physiol Rev.* 1999;79(2):451-480. doi:10.1152/physrev.1999.79.2.451
10. Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. *Cell Metab.* 2019;29(5):1028-1044. doi:10.1016/j.cmet.2019.03.009
11. Mahmoud AM. An Overview of Epigenetics in Obesity: The Role of Lifestyle and Therapeutic Interventions. *Int J Mol Sci.* 2022;23(3):1341. Published 2022 Jan 25. doi:10.3390/ijms23031341
12. Styne DM, Arslanian SA, Connor EL, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2017;102(3):709-757. doi:10.1210/jc.2016-2573
13. Cancelier ACL, Rezin GT, Fernandes J, et al. Adenovirus-36 as one of the causes of obesity: the review of the pathophysiology. *Nutr Res.* 2021;86:60-67. doi:10.1016/j.nutres.2020.12.004
14. Atkinson RL. Viruses as an etiology of obesity. *Mayo Clin Proc.* 2007;82(10):1192-1198. doi:10.4065/82.10.1192
15. Zatterale F, Longo M, Naderi J, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. *Front Physiol.* 2020;10:1607. Published 2020 Jan 29. doi:10.3389/fphys.2019.01607
16. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. *Obesity (Silver Spring).* 2014;22 Suppl 2:S5-S39. doi:10.1002/oby.20821

17. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. *Obesity (Silver Spring)*. 2014;22 Suppl 2:S41-S410. doi:10.1002/oby.20660
18. American Heart Association; American College of Cardiology; Obesity Society. Reprint: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. *J Am Pharm Assoc (2003)*. 2014;54(1):e3. doi:10.1331/japha.2014.14502
19. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2025. *Diabetes Care*. 2024;48(Supplement_1):S167-S180. doi:10.2337/dc25-S008
20. Simpson SJ, Raubenheimer D. Obesity: the protein leverage hypothesis. *Obes Rev*. 2005;6(2):133-142. doi:10.1111/j.1467-789X.2005.00178.x
21. Raubenheimer D, Simpson SJ. Protein Leverage: Theoretical Foundations and Ten Points of Clarification. *Obesity (Silver Spring)*. 2019;27(8):1225-1238. doi:10.1002/oby.22531
22. Raubenheimer D, Simpson SJ. Protein appetite as an integrator in the obesity system: the protein leverage hypothesis. *Philos Trans R Soc Lond B Biol Sci*. 2023;378(1888):20220212. doi:10.1098/rstb.2022.0212
23. Bays HE, Golden A, Tondt J. Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obesity Pillars*. 2022;3:100034. doi:10.1016/j.obpill.2022.100034
24. Casazza K, Brown A, Astrup A, et al. Weighing the Evidence of Common Beliefs in Obesity Research. *Critical Reviews in Food Science and Nutrition*. 2015;55(14):2014-2053. doi:10.1080/10408398.2014.922044
25. Casazza K, Fontaine KR, Astrup A, et al. Myths, Presumptions, and Facts about Obesity. *N Engl J Med*. 2013;368(5):446-454. doi:10.1056/NEJMsa1208051

2

Nutrition, Physical Activity, and Behavior



References

2.1 Obtain a Nutrition History

1. *Burrige K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022;1(100007).*
2. *Kesari A, Noel JY. Nutritional Assessment. In: StatPearls. StatPearls Publishing; 2025. Accessed March 28, 2025. <http://www.ncbi.nlm.nih.gov/books/NBK580496/>*
3. *Davis JN, Oaks BM, Engle-Stone R. The Double Burden of Malnutrition: A Systematic Review of Operational Definitions. Curr Dev Nutr. 2020;4(9):nzaa127. doi:10.1093/cdn/nzaa127*
4. *Wells JC, Sawaya AL, Wibaek R, et al. The double burden of malnutrition: aetiological pathways and consequences for health. Lancet. 2020;395(10217):75-88. doi:10.1016/S0140-6736(19)32472-9*
5. *Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clinical Nutrition. 2017;36(1):49-64. doi:10.1016/j.clnu.2016.09.004*
6. *Calcaterra V, Verduci E, Milanta C, et al. Micronutrient Deficiency in Children and Adolescents with Obesity—A Narrative Review. Children (Basel). 2023;10(4):695. doi:10.3390/children10040695*
7. *Kesari A, Noel JY. Nutritional Assessment. In: StatPearls. StatPearls Publishing; 2025. Accessed March 28, 2025. <http://www.ncbi.nlm.nih.gov/books/NBK580496/>*
8. *Eisenberg DM, Cole A, Maile EJ, et al. Proposed Nutrition Competencies for Medical Students and Physician Trainees: A Consensus Statement. JAMA Netw Open. 2024;7(9):e2435425. Published 2024 Sep 3. doi:10.1001/jamanetworkopen.2024.35425*
9. *Vadiveloo M, Lichtenstein AH, Anderson C, et al. Rapid Diet Assessment Screening Tools for Cardiovascular Disease Risk Reduction Across Healthcare Settings: A Scientific Statement From the American Heart Association. Circ Cardiovasc Qual Outcomes. 2020;13(9):e000094. doi:10.1161/HCQ.0000000000000094*
10. *Bradley M, Melchor J, Carr R, Karjoo S. Obesity and malnutrition in children and adults: A clinical review. Obes Pillars. 2023;8:100087. Published 2023 Sep 7. doi:10.1016/j.obpill.2023.100087*
11. *A.S.P.E.N. Clinical Guidelines. Accessed April 11, 2025. https://lh-hsrc.pnu.edu.sa/wp-content/uploads/2020/01/Mueller_et_al-2011-Journal_of_Parenteral_and_Enteral_Nutrition.pdf*
12. *Isenring EA, Bauer JD, Banks M, Gaskill D. The Malnutrition Screening Tool is a useful tool for identifying malnutrition risk in residential aged care. J Hum Nutr Diet. 2009;22(6):545-550. doi:10.1111/j.1365-277X.2009.01008.x*
13. *García-Conesa MT, Philippou E, Pafilas C, et al. Exploring the Validity of the 14-Item Mediterranean Diet Adherence Screener (MEDAS): A Cross-National Study in Seven European Countries around the Mediterranean Region. Nutrients. 2020;12(10):2960. doi:10.3390/nu12102960*
14. *Lara-Breitinger KM, Medina Inojosa JR, Li Z, et al. Validation of a Brief Dietary Questionnaire for Use in Clinical Practice: Mini-EAT (Eating Assessment Tool). J Am Heart Assoc. 2023;12(1):e025064. doi:10.1161/JAHA.121.025064*

2.2 Obtain an Eating Behavior History

1. Freshwater M, Christensen S, Oshman L, Bays HE. Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;2:100014. doi:10.1016/j.obpill.2022.100014
2. Nagata JM, Golden NH. New US Preventive Services Task Force Recommendations on Screening for Eating Disorders. *JAMA Intern Med*. 2022;182(5):471-473. doi:10.1001/jamainternmed.2022.0121
3. NCD - Intensive Behavioral Therapy for Obesity (210.12). Accessed April 12, 2025. <https://www.cms.gov/medicare-coverage-database/view/hcd.aspx?NCDId=353>
4. Nicoletti B. Behavioral Counseling for Obesity, HCPCS Code G0447. CodingIntel. July 10, 2018. Accessed April 12, 2025. <https://codingintel.com/behavioral-counseling-obesity-hcpcs-code-g0447/>
5. The Four Pillars of Obesity Treatment | Obesity Medicine Association. Obesity Medicine Association. Accessed April 12, 2025. <https://obesitymedicine.org/about/four-pillars/>
6. Alagha M, Al-Alam F, Saroufine K, et al. Binge Eating Disorder and Metabolic Syndrome: Shared Mechanisms and Clinical Implications. *Healthcare*. 2025;13(5):482. doi:10.3390/healthcare13050482
7. Eating Disorders - National Institute of Mental Health (NIMH). Accessed April 4, 2025. <https://www.nimh.nih.gov/health/statistics/eating-disorders>
8. Himmerich H, Bentley J, McElroy SL. Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. *CNS Drugs*. 2024;38(9):697-718. doi:10.1007/s40263-024-01111-1
9. Hampel SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics*. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
10. CDC. Evidence-Based Guidelines for Child Obesity. Obesity. September 20, 2024. Accessed April 12, 2025. <https://www.cdc.gov/obesity/child-obesity-strategies/evidence-based-guidelines.html>
11. Klein DA, Sylvester JE, Schvey NA. Eating Disorders in Primary Care: Diagnosis and Management. Accessed April 12, 2025. <https://www.aafp.org/pubs/afp/issues/2021/0101/p22.html>

2.3 Obtain a Physical Activity History

1. Ozemek C, Bonikowske A, Christle J, Gallo P. ACSM's Guidelines for Exercise Testing and Prescription. 12th edition. Lippincott Williams and Wilkins
2. Ceria-Ulep CD, Tse AM, Serafica RC. Defining Exercise in Contrast to Physical Activity. *Issues in Mental Health Nursing*. 2011;32(7):476-478. doi:10.3109/01612840.2010.525692
3. Bonilla DA, Stout JR, Candow DG, et al. The power of creatine plus resistance training for healthy aging: enhancing physical vitality and cognitive function. *Front Physiol*. 2024;15:1496544. doi:10.3389/fphys.2024.1496544
4. Levine JA. Non-exercise activity thermogenesis (NEAT). *Best Practice & Research Clinical Endocrinology & Metabolism*. 2002;16(4):679-702. doi:10.1053/beem.2002.0227
5. Burnet K, Kelsch E, Zieff G, Moore JB, Stoner L. How fitting is F.I.T.T.? A perspective on a transition from the sole use of frequency, intensity, time, and type in exercise prescription. *Physiology & Behavior*. 2019;199:33-34. doi:10.1016/j.physbeh.2018.11.007
6. *Physical Activity Guidelines for Americans, 2nd edition*.
7. Herrmann SD, Willis EA, Ainsworth BE, et al. 2024 Adult Compendium of Physical Activities: A third update of the energy costs of human activities. *Journal of Sport and Health Science*. 2024;13(1):6-12. doi:10.1016/j.jshs.2023.10.010
8. Target Heart Rates Chart | American Heart Association. Accessed October 28, 2025. <https://www.heart.org/en/healthy-living/fitness/fitness-basics/target-heart-rates>

9. Reed JL, Pipe AL. The talk test: a useful tool for prescribing and monitoring exercise intensity. *Current Opinion in Cardiology*. 2014;29(5):475-480. doi:10.1097/HCO.0000000000000097
10. Williams N. The Borg Rating of Perceived Exertion (RPE) scale. *Occupational Medicine*. 2017;67(5):404-405. doi:10.1093/occmed/kqx063
11. Kuntz JL, Young DR, Saelens BE, et al. Validity of the Exercise Vital Sign Tool to Assess Physical Activity. *American Journal of Preventive Medicine*. 2021;60(6):866-872. doi:10.1016/j.amepre.2021.01.012
12. Butte NF, Ekelund U, Westerterp KR. Assessing Physical Activity Using Wearable Monitors: Measures of Physical Activity. *Medicine & Science in Sports & Exercise*. 2012;44(1S):S5-S12. doi:10.1249/MSS.0b013e3182399c0e
13. Germini F, Noronha N, Borg Debono V, et al. Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature. *J Med Internet Res*. 2022;24(1):e30791. doi:10.2196/30791
14. Park CL, Finkelstein-Fox L, Groessl E, Elwy AR. Exploring How Different Types of Yoga Change Psychological Resources and Emotional Well-Being across a Single Session. *Complement Ther Med*. 2020;49:102354. doi:10.1016/j.ctim.2020.102354
15. Warburton D, Jamnik V, Bredin S, Shephard R, Gledhill N. The 2023 Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) and electronic Physical Activity Readiness Medical Examination (ePARmed-X+). *The Health & Fitness Journal of Canada*. Published online March 31, 2023:46-49 Pages. doi:10.14288/HFJC.V16I1.839
16. Fessele KL, Syrkin G. Mobility Assessment Instruments. *Seminars in Oncology Nursing*. 2024;40(4):151660. doi:10.1016/j.soncn.2024.151660
17. Lang JJ, Wolfe Phillips E, Orpana HM, et al. Field-based measurement of cardiorespiratory fitness to evaluate physical activity interventions. *Bull World Health Organ*. 2018;96(11):794-796. doi:10.2471/BLT.18.213728
18. CDC. Guidelines and Recommended Strategies. Physical Activity. April 10, 2024. Accessed October 16, 2024. <https://www.cdc.gov/physical-activity/php/guidelines-recommendations/index.html>

2.4 Obtain a Sleep History

1. Sateia MJ. *International Classification of Sleep Disorders-Third Edition*. Chest. 2014;146(5):1387-1394. doi:10.1378/chest.14-0970
2. Papakostas GI, Jackson WC, Rafeyan R, Trivedi MH. Overcoming Challenges to Treat Inadequate Response in Major Depressive Disorder. *J Clin Psychiatry*. 2020;81(3):OT19037BR4. doi:10.4088/JCP.OT19037BR4
3. Spiegel K, Tasali E, Penev P, Cauter EV. Brief Communication: Sleep Curtailment in Healthy Young Men Is Associated with Decreased Leptin Levels, Elevated Ghrelin Levels, and Increased Hunger and Appetite. *Ann Intern Med*. 2004;141(11):846-850. doi:10.7326/0003-4819-141-11-200412070-00008
4. Nedeltcheva AV, Kilkus JM, Imperial J, Schoeller DA, Penev PD. Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity. *Ann Intern Med*. 2010;153(7):435-441. doi:10.7326/0003-4819-153-7-201010050-00006
5. Chaput JP, Després JP, Bouchard C, Tremblay A. The Association Between Sleep Duration and Weight Gain in Adults: A 6-Year Prospective Study from the Quebec Family Study. *Sleep*. 2008;31(4):517-523. doi:10.1093/sleep/31.4.517
6. Chernyshev OY. Sleep Deprivation and Its Consequences. *Continuum*. 2023;29(4):1234-1252. doi:10.1212/CON.0000000000001323

7. Meyer N, Harvey AG, Lockley SW, Dijk DJ. Circadian rhythms and disorders of the timing of sleep. *The Lancet*. 2022;400(10357):1061-1078. doi:10.1016/S0140-6736(22)00877-7
8. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline. *Journal of Clinical Sleep Medicine*. 2015;11(10):1199-1236. doi:10.5664/jcsm.5100
9. McHill AW, Phillips AJ, Czeisler CA, et al. Later circadian timing of food intake is associated with increased body fat. *The American Journal of Clinical Nutrition*. 2017;106(5):1213-1219. doi:10.3945/ajcn.117.161588
10. Consens FB. Circadian Rhythm Sleep-Wake Disorders. *Continuum*. 2023;29(4):1149-1166. doi:10.1212/CON.0000000000001287
11. Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep Duration From Infancy to Adolescence: Reference Values and Generational Trends. *Pediatrics*. 2003;111(2):302-307. doi:10.1542/peds.111.2.302

2.5 Counsel on Behavior Modification

1. Dalle Grave R, Sartirana M, Calugi S. Personalized cognitive-behavioural therapy for obesity (CBT-OB): theory, strategies and procedures. *Biopsychosoc Med*. 2020;14:5. doi:10.1186/s13030-020-00177-9
2. Freshwater M, Christensen S, Oshman L, Bays HE. Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;2:100014. doi:10.1016/j.obpill.2022.100014
3. Castelnuovo G, Pietrabissa G, Manzoni GM, et al. Cognitive behavioral therapy to aid weight loss in obese patients: current perspectives. *Psychol Res Behav Manag*. 2017;10:165-173. Published 2017 Jun 6. doi:10.2147/PRBM.S113278
4. Garvey WT, Mechanick JL, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. *Endocrine Practice*. 2016;22:1-203. doi:10.4158/EP161365.GL
5. Epstein LH, Paluch RA, Kilanowski CK, Raynor HA. The effect of reinforcement or stimulus control to reduce sedentary behavior in the treatment of pediatric obesity. *Health Psychol*. 2004;23(4):371-380. doi:10.1037/0278-6133.23.4.371
6. Miller WR, Rose GS. Toward a theory of motivational interviewing. *Am Psychol*. 2009;64(6):527-537. doi:10.1037/a0016830
7. Jacob A, Moullec G, Lavoie KL, et al. Impact of cognitive-behavioral interventions on weight loss and psychological outcomes: A meta-analysis. *Health Psychol*. 2018;37(5):417-432. doi:10.1037/hea0000576
8. Vallis M, Piccinini-Vallis H, Sharma AM, Freedhoff Y. Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. *Can Fam Physician*. 2013;59(1):27-31.
9. Alexander SC, Cox ME, Boling Turer CL, et al. Do the five A's work when physicians counsel about weight loss? *Fam Med*. 2011;43(3):179-184.
10. Miller ST, Oates VJ, Brooks MA, Shintani A, Gebretsadik T, Jenkins DM. Preliminary efficacy of group medical nutrition therapy and motivational interviewing among obese African American women with type 2 diabetes: a pilot study. *J Obes*. 2014;2014:345941. doi:10.1155/2014/345941
11. Kushner RF, Ryan DH. Assessment and Lifestyle Management of Patients With Obesity: Clinical Recommendations From Systematic Reviews. *JAMA*. 2014;312(9):943. doi:10.1001/jama.2014.10432

12. Chew HSJ, Chng S, Rajasegaran NN, Choy KH, Chong YY. Effectiveness of acceptance and commitment therapy on weight, eating behaviours and psychological outcomes: a systematic review and meta-analysis. *Eat Weight Disord.* 2023;28(1):6. doi:10.1007/s40519-023-01535-6
13. LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2018;320(11):1172-1191. doi:10.1001/jama.2018.7777
14. Vuorinen AL, Helander E, Pietilä J, Korhonen I. Frequency of Self-Weighing and Weight Change: Cohort Study With 10,000 Smart Scale Users. *J Med Internet Res.* 2021;23(6):e25529. doi:10.2196/25529
15. Howlett N, Trivedi D, Troop NA, Chater AM. Are physical activity interventions for healthy inactive adults effective in promoting behavior change and maintenance, and which behavior change techniques are effective? A systematic review and meta-analysis. *Transl Behav Med.* 2019;9(1):147-157. doi:10.1093/tbm/iby010
16. Lemstra M, Bird Y, Nwankwo C, Rogers M, Moraros J. Weight loss intervention adherence and factors promoting adherence: a meta-analysis. *Patient Prefer Adherence.* 2016;10:1547-1559. doi:10.2147/PPA.S103649
17. Van Dorsten B, Lindley EM. Cognitive and behavioral approaches in the treatment of obesity. *Med Clin North Am.* 2011;95(5):971-988. doi:10.1016/j.mcna.2011.06.008
18. Krebs P, Norcross JC, Nicholson JM, Prochaska JO. Stages of change and psychotherapy outcomes: A review and meta-analysis. *J Clin Psychol.* 2018;74(11):1964-1979. doi:10.1002/jclp.22683
19. Xu R, Bannor R, Cardel MI, Foster GD, Pagoto S. How much food tracking during a digital weight-management program is enough to produce clinically significant weight loss? *Obesity (Silver Spring).* 2023;31(7):1779-1786. doi:10.1002/oby.23795
20. Miller NH. Motivational interviewing as a prelude to coaching in healthcare settings. *J Cardiovasc Nurs.* 2010;25(3):247-251. doi:10.1097/JCN.0b013e3181cec6e7
21. Westra HA, Aviram A. Core skills in motivational interviewing. *Psychotherapy (Chic).* 2013;50(3):273-278. doi:10.1037/a0032409
22. Patel ML, Wakayama LN, Bennett GG. Self-Monitoring via Digital Health in Weight Loss Interventions: A Systematic Review Among Adults with Overweight or Obesity. *Obesity (Silver Spring).* 2021;29(3):478-499. doi:10.1002/oby.23088

2.6 Counsel on Nutrition

1. Martínez-González MÁ, Hernández Hernández A. Effect of the Mediterranean diet in cardiovascular prevention. *Rev Esp Cardiol (Engl Ed).* 2024;77(7):574-582. doi:10.1016/j.rec.2024.01.006
2. Singh A, Singh D. The Paleolithic Diet. *Cureus.* 2023;15(1):e34214. Published 2023 Jan 25. doi:10.7759/cureus.34214
3. Ornish D. *Everyday cooking with Dean Ornish.* New York, NY: HarperCollins Publishers; 1996.
4. *Therapeutic Lifestyle Changes (TLC) to Lower Cholesterol.* NHLBI, NIH. Accessed October 24, 2025. <https://www.nhlbi.nih.gov/education/TLC-Therapeutic-Lifestyle-Changes-Lower-Cholesterol>
5. Castro-Barquero S, Ruiz-León AM, Sierra-Pérez M, Estruch R, Casas R. Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. *Nutrients.* 2020;12(10):2983. Published 2020 Sep 29. doi:10.3390/nu12102983
6. Karjoo S, Braglia-Tarpey A, Chan AP, et al. Evidence-based review of the nutritional treatment of obesity and metabolic dysfunction-associated steatotic liver disease in children and adolescents. *J Pediatr Gastroenterol Nutr.* 2025;81(3):485-496. doi:10.1002/jpn3.70099
7. Imbus JR, Voils CI, Funk LM. Bariatric surgery barriers: a review using Andersen's Model of Health Services Use. *Surg Obes Relat Dis.* 2018;14(3):404-412. doi:10.1016/j.soard.2017.11.012

8. Mocanu V, Dang JT, Switzer N, Madsen K, Birch DW, Karmali S. Sex and Race Predict Adverse Outcomes Following Bariatric Surgery: an MBSAQIP Analysis. *Obes Surg.* 2020;30(3):1093-1101. doi:10.1007/s11695-020-04395-6
9. U.S. Department of Agriculture and U.S. Department of Health and Human Services. *Dietary Guidelines for Americans, 2020-2025.* U.S. Government Printing Office; 2020. Accessed September 14, 2025. <https://www.dietaryguidelines.gov/>
10. Wansink B, Wansink A. MyPlate, Half-Plate, and No Plate: How Visual Plate-Related Dietary Benchmarks Influence What Food People Serve. *Cureus.* 2022;14(5):e25231. Published 2022 May 23. doi:10.7759/cureus.25231
11. Wei X, Lin B, Huang Y, et al. Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial. *JAMA Netw Open.* 2023;6(3):e233513. Published 2023 Mar 1. doi:10.1001/jamanetworkopen.2023.3513
12. Feehan J, Mack A, Tuck C, et al. Time-Restricted Fasting Improves Liver Steatosis in NonAlcoholic Fatty Liver Disease—A Single Blinded Crossover Trial. *Nutrients.* 2023;15(23):4870. Published 2023 Nov 22. doi:10.3390/nu15234870
13. Ezpeleta M, Gabel K, Cienfuegos S, et al. Effect of alternate day fasting combined with aerobic exercise on nonalcoholic fatty liver disease: A randomized controlled trial. *Cell metabolism.* 2023;35(1):56–70.e3. doi: 10.1016/j.cmet.2022.12.001.
14. Kord Varkaneh H, Salehi Sahlabadi A, Găman MA, et al. Effects of the 5:2 intermittent fasting diet on nonalcoholic fatty liver disease: A randomized controlled trial. *Front Nutr.* 2022;9:948655. Published 2022 Jul 26. doi:10.3389/fnut.2022.948655
15. Johari MI, Yusoff K, Haron J, et al. A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of NonAlcoholic Fatty Liver Disease. *Sci Rep.* 2019;9(1):11232. Published 2019 Aug 2. doi:10.1038/s41598-019-47763-8
16. Holmer M, Lindqvist C, Petersson S, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. *JHEP Rep.* 2021;3(3):100256. Published 2021 Feb 17. doi:10.1016/j.jhepr.2021.100256
17. Lin X, Wang S, Huang J. The effects of time-restricted eating for patients with nonalcoholic fatty liver disease: a systematic review. *Front Nutr.* 2024;10:1307736. Published 2024 Jan 4. doi:10.3389/fnut.2023.1307736
18. de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease. *N Engl J Med.* 2019;381(26):2541-2551. doi:10.1056/NEJMr1905136
19. Mulligan CM, Friedman JE. Maternal modifiers of the infant gut microbiota: metabolic consequences. *J Endocrinol.* 2017;235(1):R1-R12. doi:10.1530/JOE-17-0303
20. Woo Baidal JA, Locks LM, Cheng ER, Blake-Lamb TL, Perkins ME, Taveras EM. Risk Factors for Childhood Obesity in the First 1,000 Days: A Systematic Review. *Am J Prev Med.* 2016;50(6):761-779. doi:10.1016/j.amepre.2015.11.012
21. Blake-Lamb TL, Locks LM, Perkins ME, Woo Baidal JA, Cheng ER, Taveras EM. Interventions for Childhood Obesity in the First 1,000 Days A Systematic Review. *Am J Prev Med.* 2016;50(6):780-789. doi:10.1016/j.amepre.2015.11.010
22. Freemark MS. *Pediatric Obesity Etiology, Pathogenesis and Treatment.* Humana Press; 2018.
23. Wadden TA, Bray GA, eds. *Handbook of Obesity Treatment.* 2nd ed. The Guilford Press; 2018.
24. Rippe JM, Foreyt JP, eds. *Obesity Prevention and Treatment: A Practical Guide.* CRC Press; 2021. doi:10.1201/9781003099116
25. Fox CK. *Managing pediatric obesity using advanced therapies: Practical guide for pediatric health care providers.* Springer International Publishing; 2023. doi: 10.1007/978-3-031-37380-0
26. Bray GA, Katzmarzyk PT, Bouchard C, Kirwan JP, Redman LM, Schauer PR, eds. *Handbook of Obesity, Two-Volume Set.* 5th ed. CRC Press; 2024. doi:10.1201/9781003437734

27. Apovian CM, Aronne LJ, Barenbaum S. *Clinical Management of Obesity*. Professional Communications, Inc; 2023.
28. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. *CMAJ*. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707
29. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2020;324(20):2069-2075. doi:10.1001/jama.2020.21749
30. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2022;328(4):367-374. doi:10.1001/jama.2022.10951
31. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics*. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640

2.7 Counsel on Physical Activity

1. *Physical Activity Guidelines for Americans, 2nd edition*. Accessed April 28, 2025. https://odphp.health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf#page=108
2. Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. *Med Sci Sports Exerc*. 2009;41(2):459-471. doi:10.1249/MSS.0b013e3181949333
3. Jakicic JM, Apovian CM, Barr-Anderson DJ, et al. Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement. *Med Sci Sports Exerc*. 2024;56(10):2076-2091. doi:10.1249/MSS.0000000000003520
4. Alexander L, Christensen SM, Richardson L, et al. Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022. *Obes Pillars*. 2022;1:100005. doi:10.1016/j.obpill.2021.100005
5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. *Circulation*. 2014;129(25_suppl_2):S102-S138. doi:10.1161/01.cir.0000437739.71477.ee
6. Creasy SA, Lang W, Tate DF, Davis KK, Jakicic JM. Pattern of Daily Steps is Associated with Weight Loss: Secondary Analysis from the Step-Up Randomized Trial. *Obesity*. 2018;26(6):977-984. doi:10.1002/oby.22171
7. Park JH, Moon JH, Kim HJ, Kong MH, Oh YH. Sedentary Lifestyle: Overview of Updated Evidence of Potential Health Risks. *Korean J Fam Med*. 2020;41(6):365-373. doi:10.4082/kjfm.20.0165
8. Oppert JM, Bellicha A, van Baak MA, et al. Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group. *Obesity Reviews*. 2021;22(S4):e13273. doi:10.1111/obr.13273
9. Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. *New England Journal of Medicine*. 2021;384(18):1719-1730. doi:10.1056/NEJMoa2028198
10. Jakicic, J. M., Apovian, C. M., Barr-Anderson, D. J., Courcoulas, A. P., Donnelly, J. E., Ekkekakis, P., ... & Volpe, S. L. (2024). Physical activity and excess body weight and adiposity for adults. American College of Sports Medicine Consensus Statement. *Translational Journal of the American College of Sports Medicine*, 9(4), e000266.

2.8 Formulate an Effective Treatment Plan

1. WHO Expert Consultation. *Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.* *Lancet.* 2004;363(9403):157-163. doi:10.1016/S0140-6736(03)15268-3
2. Li Z, Daniel S, Fujioka K, Umashanker D. *Obesity among Asian American people in the United States: A review.* *Obesity (Silver Spring).* 2023;31(2):316-328. doi:10.1002/oby.23639
3. Rubino F, Cummings DE, Eckel RH, et al. *Definition and diagnostic criteria of clinical obesity.* *Lancet Diabetes Endocrinol.* 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4
4. Kushner RF, Ryan DH. *Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews.* *JAMA.* 2014;312(9):943-952. doi:10.1001/jama.2014.10432
5. *Corrigendum.* *The Journal of Clinical Endocrinology & Metabolism.* 2015;100(5):2135-2136. doi:10.1210/jc.2015-1782
6. Hill JO, Wyatt HR, Peters JC. *Energy balance and obesity.* *Circulation.* 2012;126(1):126-132. doi:10.1161/CIRCULATIONAHA.111.087213
7. Ryan DH, Yockey SR. *Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over.* *Curr Obes Rep.* 2017;6(2):187-194. doi:10.1007/s13679-017-0262-y
8. Pérez-Escamilla R. *Food Security and the 2015-2030 Sustainable Development Goals: From Human to Planetary Health: Perspectives and Opinions.* *Curr Dev Nutr.* 2017;1(7):e000513. Published 2017 Jun 20. doi:10.3945/cdn.117.000513
9. Leung CW, Ding EL, Catalano PJ, Villamor E, Rimm EB, Willett WC. *Dietary intake and dietary quality of low-income adults in the Supplemental Nutrition Assistance Program.* *Am J Clin Nutr.* 2012;96(5):977-988. doi:10.3945/ajcn.112.040014
10. Soneji S, Beltrán-Sánchez H. *Association of Special Supplemental Nutrition Program for Women, Infants, and Children With Preterm Birth and Infant Mortality.* *JAMA Netw Open.* 2019;2(12):e1916722. Published 2019 Dec 2. doi:10.1001/jamanetworkopen.2019.16722
11. Apolzan JW, Venditti EM, Edelstein SL, et al. *Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.* *Ann Intern Med.* 2019;170(10):682-690. doi:10.7326/M18-1605

2.9 Manage the Obesity Treatment Plan Long-Term

1. Hall KD, Kahan S. *Maintenance of Lost Weight and Long-Term Management of Obesity.* *Medical Clinics of North America.* 2018;102(1):183-197. doi:10.1016/j.mcna.2017.08.012
2. Bray GA, Kim KK, Wilding JPH, on behalf of the World Obesity Federation. *Obesity: a chronic, relapsing, progressive disease process. A position statement of the World Obesity Federation.* *Obesity Reviews.* 2017;18(7):715-723. doi:10.1111/obr.12551
3. Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L. *Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines.* *Obesity Reviews.* 2017;18(12):1377-1385. doi:10.1111/obr.12606
4. Sjöström L, Narbro K, Sjöström CD, et al. *Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects.* *N Engl J Med.* 2007;357(8):741-752. doi:10.1056/nejmoa066254
5. Shai I, Schwarzfuchs D, Henkin Y, et al. *Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet.* *N Engl J Med.* 2008;359(3):229-241. doi:10.1056/nejmoa0708681

6. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA*. 2021;325(14):1414. doi:10.1001/jama.2021.3224
7. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. *JAMA*. 2024;331(1):38. doi:10.1001/jama.2023.24945
8. Wing RR, Phelan S. Long-term weight loss maintenance. *The American Journal of Clinical Nutrition*. 2005;82(1):222S-225S. doi:10.1093/ajcn/82.1.222S
9. Ross R, Latimer-Cheung AE, Day AG, Brennan AM, Hill JO. A small change approach to prevent long-term weight gain in adults with overweight and obesity: a randomized controlled trial. *CMAJ*. 2022;194(9):E324-E331. doi:10.1503/cmaj.211041
10. Jakicic JM. Effect of Exercise on 24-Month Weight Loss Maintenance in Overweight Women. *Arch Intern Med*. 2008;168(14):1550. doi:10.1001/archinte.168.14.1550
11. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. *Obesity*. 2016;24(8):1612-1619. doi:10.1002/oby.21538
12. Martins C, Roekenes J, Salamati S, Gower BA, Hunter GR. Metabolic adaptation is an illusion, only present when participants are in negative energy balance. *Am J Clin Nutr*. 2020;112(5):1212-1218. doi:10.1093/ajcn/nqaa220
13. Martins C, Gower BA, Hill JO, Hunter GR. Metabolic adaptation is not a major barrier to weight-loss maintenance. *Am J Clin Nutr*. 2020;112(3):558-565. doi:10.1093/ajcn/nqaa086

3

Medications and Bariatric Procedures



References

3.1 Obtain a Medication and Supplement History

1. Tondt J, Bays HE. Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;2:100017. doi:10.1016/j.obpill.2022.100017
2. Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: A systematic review. *Obes Rev*. 2019;20(12):1680-1690. doi:10.1111/obr.12934
3. Cornier MA. A review of current guidelines for the treatment of obesity. *Am J Manag Care*. 2022;28(15 Suppl):S288-S296. doi:10.37765/ajmc.2022.89292
4. Strategies to Overcome and Prevent (STOP) Obesity Alliance. Fast Facts – Obesity-Related Chronic Disease. Milken Institute School of Public Health, George Washington University. February 26, 2020. Accessed October 21, 2025. <https://stop.publichealth.gwu.edu/fast-facts/obesity-related-chronic-disease>
5. Erlandson M, Ivey LC, Seikel K. Update on Office-Based Strategies for the Management of Obesity. *Am Fam Physician*. 2016;94(5):361-368.
6. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2015;100(2):342-362. doi:10.1210/jc.2014-3415
7. National Institutes of Health Office of Dietary Supplements. Dietary Supplements for Weight Loss: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements. May 18, 2022. Accessed October 21, 2025. <https://ods.od.nih.gov/factsheets/WeightLoss-HealthProfessional/>
8. Tarn DM, Guzmán JR, Good JS, Wenger NS, Coulter ID, Paterniti DA. Provider and patient expectations for dietary supplement discussions. *J Gen Intern Med*. 2014;29(9):1242-1249. doi:10.1007/s11606-014-2899-5
9. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2015;100(2):363-370. doi:10.1210/jc.2014-3421
10. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA recommends against the continued use of Meridia (sibutramine). Silver Spring (MD): U.S. Food and Drug Administration. October 8, 2010. Accessed June 17, 2025. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-against-continued-use-meridia-sibutramine>
11. U.S. Food and Drug Administration. FDA Drug Safety Podcast: FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. Silver Spring (MD): U.S. Food and Drug Administration. February 13, 2020. Accessed June 17, 2025. <https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market>
12. Barrea L, Altieri B, Polese B, De Conno B, Muscogiuri G, Colao A, Savastano S; Obesity Programs of Nutrition, Education, Research and Assessment (OPERA) Group. Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. *Int J Obes Suppl*. 2019;9:32–49. doi: 10.1038/s41367-019-0007-3
13. Dini I, Mancusi A. Weight Loss Supplements. *Molecules*. 2023;28(14):5357. Published 2023 Jul 12. doi:10.3390/molecules28145357
14. Centers for Disease Control and Prevention. Cardiac Valvulopathy Associated with Exposure to Fenfluramine or Dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations, November 1997. Accessed October 21, 2025. <https://www.cdc.gov/mmwr/preview/mmwrhtml/00049815.htm>

15. Gast A, Mathes T. Medication adherence influencing factors—an (updated) overview of systematic reviews. *Systematic Reviews*. 2019;8(1):112. doi:10.1186/s13643-019-1014-8
16. Brown MT, Bussell JK. Medication adherence: WHO cares?. *Mayo Clin Proc*. 2011;86(4):304-314. doi:10.4065/mcp.2010.0575

3.2 Prescribe Obesity Medications

1. Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. *Obesity*. 2019 Apr;27(4):591-602.
2. Tchang BC, Aras M, Kumar RB, Aronne LJ. Pharmacologic Treatment of Overweight and Obesity in Adults. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2025 Aug 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK279038/>
3. Mula M. Topiramate and cognitive impairment: evidence and clinical implications. *Therapeutic Advances in Drug Safety*. 2012 Dec;3(6):279-89.
4. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational Design of a Combination Medication for the Treatment of Obesity. *Obesity*. 2009 Jan;17(1):30-9.
5. Moiz A, Fillion KB, Tsoukas MA, Yu OHy, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. *The American Journal of Medicine*. 2025 June;138(6):934-40.
6. Kagdi S, Lyons SA, Beaudry JL. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. *Journal of Endocrinology*. 2024 Apr 3;261(3):e230361.
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023 Dec 14;389(24):2221-32.
8. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2023 Sept 21;389(12):1069-84.
9. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2025 Jan 30;392(5):427-37.
10. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N Engl J Med*. 2024 Oct 3;391(13):1193-205.
11. Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. *N Engl J Med*. 2025 June 5;392(21):2089-99.
12. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. *N Engl J Med*. 2024 July 25;391(4):299-310.
13. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med*. 2024 July 11;391(2):109-21.
14. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. *Obes Rev*. 2014;15:578-86.
15. Gudbergson H, Overgaard A, Henriksen M, Wæhrens EE, Bliddal H, Christensen R, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. *Am J Clin Nutr*. 2021 Feb 2;113(2):314-23.

16. Little TJ, Horowitz M, Feinle-Bisset C. Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity. *The American Journal of Clinical Nutrition*. 2007 Sept;86(3):531–41.
17. Spinelli KJ, Oakes AH, Chiu ST, Imboden MT, Miller A, Jain S, et al. Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists. *American Journal of Medicine Open*. 2025 June;13:100100.
18. Hendricks EJ, Srisurapanont M, Schmidt SL, Haggard M, Souter S, Mitchell CL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. *Int J Obes*. 2014 Feb;38(2):292–8.
19. Hsu AY, Kuo HT, Wang YH, Lin CJ, Shao YC, Chiang CC, et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes. *JAMA Ophthalmol*. 2025 May 1;143(5):400.
20. Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, et al. The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy. *American Journal of Ophthalmology*. 2025 June;274:24–31.
21. Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. *Diabetes, Obesity and Metabolism*. 2025;27(5):2720–9.
22. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. *N Engl J Med*. 2025 July 3;393(1):26–36.
23. Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. Buchowski MS, editor. *PLoS ONE*. 2019 Sept 23;14(9):e0221615.
24. Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, et al. Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. *JNCI Journal of the National Cancer Institute*. 2015 Mar 4;107(3):djv006–djv006.
25. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. *Diabetes Care*. 2008 Sept 1;31(9):1816–23.
26. Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. *Obesity Reviews [Internet]*. 2011 May [cited 2025 Aug 11];12(5). Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1467-789X.2010.00846.x>
27. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR Enhances Weight Loss: A 48-Week Double-Blind, Placebo- Controlled Trial. *Obesity Research*. 2002 July;10(7):633–41.
28. Grilo CM, Ivezaj V, Yurkow S, Tek C, Wiedemann AA, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. *Psychol Med*. 2024 Sept;54(12):3334–44.
29. Ellul P, Delorme R, Cortese S. Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis. *CNS Drugs*. 2018 Dec;32(12):1103–12.
30. Grilo CM, Ivezaj V, Tek C, Yurkow S, Wiedemann AA, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. *AJP*. 2025 Feb 1;182(2):209–18.
31. Heymsfield SB. Dietary Supplements for Weight Loss. *Gastroenterology Clinics of North America*. 2023 June;52(2):457–67.

32. Jäger R, Abou Sawan S, Purpura M, Grube B, Röske Y, De Costa P, et al. Proprietary alpha-amylase inhibitor formulation from white kidney bean (*Phaseolus vulgaris* L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial. *Sci Rep*. 2024 June 3;14(1):12685.
33. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. *eClinicalMedicine*. 2023 Apr;58:101882.
34. Kadowaki T, Heftdal LD, Ko HJ, Overvad M, Shimomura I, Thamattoor UK, et al. Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. *JAMA Intern Med* [Internet]. 2025 Aug 4 [cited 2025 Aug 11]; Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836932>
35. Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. *N Engl J Med*. 2025 June 21;NEJMoa2505669.
36. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. *Obes Res*. 2002 Jul;10(7):633-41. doi: 10.1038/oby.2002.86. PMID: 12105285.

3.3 Provide Periprocedural Care for Bariatric Devices & Non-Surgical Procedures

1. Bray GA, Katzmarzyk PT, Bouchard C, Kirwan JP, Redman LM, Schauer PR, eds. *Handbook of Obesity, Two-Volume Set*. 5th ed. CRC Press; 2024. doi:10.1201/9781003437734
2. Apovian CM, Aronne LJ, Barenbaum S. *Clinical Management of Obesity*. Professional Communications, Inc; 2023.
3. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. *CMAJ*. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707
4. Imbus JR, Voils CI, Funk LM. Bariatric surgery barriers: a review using Andersen's Model of Health Services Use. *Surg Obes Relat Dis*. 2018;14(3):404-412. doi:10.1016/j.soard.2017.11.012
5. Mocanu V, Dang JT, Switzer N, Madsen K, Birch DW, Karmali S. Sex and Race Predict Adverse Outcomes Following Bariatric Surgery: an MBSAQIP Analysis. *Obes Surg*. 2020;30(3):1093-1101. doi:10.1007/s11695-020-04395-6

3.4 Provide Perioperative Care for Metabolic & Bariatric Surgery

1. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. *Surgery for Obesity and Related Diseases*. 2022;18(12):1345-1356. doi:10.1016/j.soard.2022.08.013
2. Mechanick JI, Apovian C, Brethauer S, et al. CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY. *Endocr Pract*. 2019;25(12):1346-1359. doi:10.4158/GL-2019-0406
3. Tabesh MR, Eghtesadi M, Abolhasani M, Maleklou F, Ejtehadi F, Alizadeh Z. Nutrition, Physical Activity, and Prescription of Supplements in Pre- and Post-bariatric Surgery Patients: An Updated Comprehensive Practical Guideline. *OBES SURG*. 2023;33(8):2557-2572. doi:10.1007/s11695-023-06703-2

4. Stenberg E, dos Reis Falcão LF, O’Kane M, et al. Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update. *World J Surg.* 2022;46(4):729-751. doi:10.1007/s00268-021-06394-9
5. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. *N Engl J Med.* 2017;376(7):641-651. doi:10.1056/NEJMoa1600869
6. Shetye B, Hamilton FR, Bays HE. Bariatric surgery, gastrointestinal hormones, and the microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars.* 2022;2:100015. doi:10.1016/j.obpill.2022.100015
7. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. *Surg Obes Relat Dis.* 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025
8. Khalaj A, Barzin M, Ebadinejad A, et al. Revisional Bariatric Surgery due to Complications: Indications and Outcomes. *OBES SURG.* 2023;33(11):3463-3471. doi:10.1007/s11695-023-06832-8
9. Ha J, Kwon Y, Kwon JW, et al. Micronutrient status in bariatric surgery patients receiving postoperative supplementation per guidelines: Insights from a systematic review and meta-analysis of longitudinal studies. *Obes Rev.* 2021;22(7):e13249. doi:10.1111/obr.13249
10. Cadejian FA, Silva OS. Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. *Diabetes Metab Syndr Obes.* 2016;9:443-446. doi:10.2147/DMSO.S123244
11. Michalsky M, Reichard K, Inge T, Pratt J, Lenders C, American Society for Metabolic and Bariatric Surgery. ASMBS pediatric committee best practice guidelines. *Surg Obes Relat Dis.* 2012;8(1):1-7. doi:10.1016/j.soard.2011.09.009
12. Khatrab MA, Mohammed ATA, Alqahtani AZM, et al. The Role of Ethnic Disparities in the Outcomes of Bariatric Surgery: A Systematic Review and Meta-Analysis. *Cureus.* 14(5):e24743. doi:10.7759/cureus.24743

3.5 Tailor Treatment for Special Populations with Obesity

1. Dutton GR, Kim Y, Jacobs DR, et al. 25-year weight gain in a racially balanced sample of U.S. adults: The CARDIA study. *Obesity (Silver Spring).* 2016;24(9):1962-1968. doi:10.1002/oby.21573
2. Martin JC, Awoke MA, Misso ML, Moran LJ, Harrison CL. Preventing weight gain in adults: A systematic review and meta-analysis of randomized controlled trials. *Obes Rev.* 2021;22(10):e13280. doi:10.1111/obr.13280
3. Tondt J, Bays HE. Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars.* 2022;2:100017. doi:10.1016/j.obpill.2022.100017
4. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism.* 2015;100(2):342-362. doi:10.1210/jc.2014-3415
5. Ghush W, Hurtado MD, Acosta A. Weight-centric treatment of type 2 diabetes mellitus. *Obes Pillars.* 2022;4:100045. doi:10.1016/j.obpill.2022.100045
6. Haber R, Zarzour F, Ghezzawi M, et al. The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Obes Metab.* 2024;26(5):1850-1867. doi:10.1111/dom.15501
7. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. *Ann Intern Med.* 2019;170(10):682-690. doi:10.7326/M18-1605

8. Anekwe CV, Ahn YJ, Bajaj SS, Stanford FC. Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: A review. *Ann N Y Acad Sci.* 2024;1533(1):145-155. doi:10.1111/nyas.15112
9. Gammone MA, Efthymakis K, D'Orazio N. Effect of Third-Generation Beta Blockers on Weight Loss in a Population of Overweight-Obese Subjects in a Controlled Dietary Regimen. *J Nutr Metab.* 2021;2021:5767306. doi:10.1155/2021/5767306
10. Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RA. Medications that cause weight gain and alternatives in Canada: a narrative review. *Diabetes Metab Syndr Obes.* 2018;11:427-438. doi:10.2147/DMSO.S171365
11. DiNicolantonio JJ, Fares H, Niazi AK, et al. -Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. *Open Heart.* 2015;2(1):e000230. doi:10.1136/openhrt-2014-000230
12. Liang L, Kung JY, Mitchelmore B, Cave A, Banh HL. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis. *J Clin Hypertens (Greenwich).* 2022;24(5):536-554. doi:10.1111/jch.14436
13. Wajid I, Vega A, Thornhill K, et al. Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review. *Life (Basel).* 2023;13(9):1845. doi:10.3390/life13091845
14. McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic Drug-Related Weight Gain and Its Treatment. *Am J Psychiatry.* 2024;181(1):26-38. doi:10.1176/appi.ajp.20230922
15. Gill H, Gill B, El-Halabi S, et al. Antidepressant Medications and Weight Change: A Narrative Review. *Obesity (Silver Spring).* 2020;28(11):2064-2072. doi:10.1002/oby.22969
16. Petimar J, Young JG, Yu H, et al. Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study. *Ann Intern Med.* 2024;177(8):993-1003. doi:10.7326/M23-2742
17. Peterlin BL, Bond DS, Ailani J, et al. Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis. *Cephalalgia.* 2024;44(12):3331024241299753. doi:10.1177/03331024241299753
18. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. *Obes Res.* 2004;12(10):1658-1669. doi:10.1038/oby.2004.206
19. Carr MM, Lou R, Macdonald-Gagnon G, et al. Weight change among patients engaged in medication treatment for opioid use disorder: a scoping review. *Am J Drug Alcohol Abuse.* 2023;49(5):551-565. doi:10.1080/00952990.2023.2207720
20. Ikeda H, Yonemochi N, Ardianto C, Yang L, Kamei J. Pregabalin increases food intake through dopaminergic systems in the hypothalamus. *Brain Res.* 2018;1701:219-226. doi:10.1016/j.brainres.2018.09.026
21. Smith ME, Lee JS, Bonham A, et al. Effect of new persistent opioid use on physiologic and psychologic outcomes following bariatric surgery. *Surg Endosc.* 2019;33(8):2649-2656. doi:10.1007/s00464-018-6542-0
22. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry.* 2020;7(1):64-77. doi:10.1016/S2215-0366(19)30416-X
23. Ishikawa S, Hashimoto N, Okubo R, et al. Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study. *Prog Neuropsychopharmacol Biol Psychiatry.* 2025;136:111231. doi:10.1016/j.pnpbp.2024.111231
24. Skelley JW, Swearingin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. *J Am Pharm Assoc (2003).* 2024;64(1):204-211.e4. doi:10.1016/j.japh.2023.10.037

25. Arunachalam A, Nguyen A, Shah NL. THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives. *Journal of the Endocrine Society*. 2023;7(Supplement_1):bvad114.692. doi:10.1210/jendso/bvad114.692
26. Nuako A, Tu L, Reyes KJC, Chhabria SM, Stanford FC. Pharmacologic Treatment of Obesity in Reproductive Aged Women. *Curr Obstet Gynecol Rep*. 2023;12(2):138-146. doi:10.1007/s13669-023-00350-1
27. Duah J, Seifer DB. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. *Reprod Biol Endocrinol*. 2025;23(1):2. doi:10.1186/s12958-024-01339-y
28. Phentermine HCL/Topiramate Extended Release Prescribing Information (QSYMIA. <http://www.vivus.com/docs/QsymiaPI.pdf>
29. Chang JJ, Lathi RB, Kim SH. A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes. *Endocr Pract*. 2020;26(9):990-996. doi:10.4158/EP-2019-0609
30. Schlatter J. Oral Contraceptives after Bariatric Surgery. *Obes Facts*. 2017;10(2):118-126. doi:10.1159/000449508
31. Rasmussen KM, Catalano PM, Yaktine AL. New guidelines for weight gain during pregnancy: what obstetrician/gynecologists should know. *Curr Opin Obstet Gynecol*. 2009;21(6):521-526. doi:10.1097/GCO.0b013e328332d24e
32. Deputy NP, Sharma AJ, Kim SY, Olson CK. Achieving Appropriate Gestational Weight Gain: The Role of Healthcare Provider Advice. *J Womens Health (Larchmt)*. 2018;27(5):552-560. doi:10.1089/jwh.2017.6514
33. Benhalima K, Minschart C, Ceulemans D, et al. Screening and Management of Gestational Diabetes Mellitus after Bariatric Surgery. *Nutrients*. 2018;10(10):1479. doi:10.3390/nu10101479
34. Dominguez JE, Cantrell S, Habib AS, et al. Society of Anesthesia and Sleep Medicine and the Society for Obstetric Anesthesia and Perinatology Consensus Guideline on the Screening, Diagnosis, and Treatment of Obstructive Sleep Apnea in Pregnancy. *Obstet Gynecol*. 2023;142(2):403-423. doi:10.1097/AOG.0000000000005261
35. Stang J, Huffman LG. Position of the Academy of Nutrition and Dietetics: Obesity, Reproduction, and Pregnancy Outcomes. *J Acad Nutr Diet*. 2016;116(4):677-691. doi:10.1016/j.jand.2016.01.008
36. Thangaratnam S. Diet and lifestyle interventions for obese pregnant women. *The Lancet Diabetes & Endocrinology*. 2015;3(10):748-749. doi:10.1016/S2213-8587(15)00253-3
37. Magro-Malosso ER, Saccone G, Di Mascio D, Di Tommaso M, Berghella V. Exercise during pregnancy and risk of preterm birth in overweight and obese women: a systematic review and meta-analysis of randomized controlled trials. *Acta Obstet Gynecol Scand*. 2017;96(3):263-273. doi:10.1111/aogs.13087
38. Foster GD, Wyatt HR, Hill JO. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. *Ann Intern Med*. 2010;153:147-157.
39. Tschiderer L, Seekircher L, Kunutsor SK, Peters SAE, O'Keefe LM, Willeit P. Breastfeeding Is Associated With a Reduced Maternal Cardiovascular Risk: Systematic Review and Meta-Analysis Involving Data From 8 Studies and 1 192 700 Parous Women. *J Am Heart Assoc*. 2022;11(2):e022746. doi:10.1161/JAHA.121.022746
40. Chowdhury R, Sinha B, Sankar MJ, et al. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. *Acta Paediatr*. Published online 2015:104 467 96-113. doi:10.1111/apa.13102
41. Marlatt KL, Pitynski-Miller DR, Gavin KM, et al. Body composition and cardiometabolic health across the menopause transition. *Obesity (Silver Spring)*. 2022;30(1):14-27. doi:10.1002/oby.23289

42. Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study. *Menopause*. 2000;7(2):96-104. doi:10.1097/00042192-200007020-00005
43. Thorneycroft IH, Lindsay R, Pickar JH. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. *Am J Obstet Gynecol*. 2007;197(2):137.e1-7. doi:10.1016/j.ajog.2007.05.042
44. Ambikairajah A, Walsh E, Tabatabaei-Jafari H, Cherbuin N. Fat mass changes during menopause: a metaanalysis. *Am J Obstet Gynecol*. 2019;221(5):393-409.e50. doi:10.1016/j.ajog.2019.04.023
45. Jensen LB, Vestergaard P, Hermann AP, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. *J Bone Miner Res*. 2003;18(2):333-342. doi:10.1359/jbmr.2003.18.2.333
46. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
47. Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. *Menopause*. 2024;31(4):266-274. doi:10.1097/GME.0000000000002310
48. U.S. Department of Agriculture and U.S. Department of Health and Human Services. *Dietary Guidelines for Americans, 2020-2025*. 9th ed. U.S. Government Printing Office; 2020. Accessed September 14, 2025. <https://www.dietaryguidelines.gov/>
49. Deutz NEP, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. *Clin Nutr*. 2014;33(6):929-936. doi:10.1016/j.clnu.2014.04.007
50. Azar AM, others. *Physical Activity Guidelines for Americans*. 2nd ed. U.S. Department of Health and Human Services; 2018. Accessed September 14, 2025. https://odphp.health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf
51. Batsis JA, Porter Starr KN, Villareal DT. Should the Incretin hype be the same for older adults: Promise + cautions. *J Am Geriatr Soc*. 2024;72(7):2266-2268. doi:10.1111/jgs.18816
52. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
53. Chanem OM, Pita A, Nazzal M, et al. Obesity, organ failure, and transplantation: a review of the role of metabolic and bariatric surgery in transplant candidates and recipients. *Surg Endosc*. 2024;38(8):4138-4151. doi:10.1007/s00464-024-10930-8
54. Lazarus E, Bays HE. Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;3:100026. doi:10.1016/j.obpill.2022.100026
55. Luo J, Hendryx M, Manson JE, et al. Intentional Weight Loss and Obesity-Related Cancer Risk. *JNCI Cancer Spectr*. 2019;3(4):pkz054. doi:10.1093/jncics/pkz054
56. Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. *Cancers (Basel)*. Published online January 12, 2023. doi:10.3390/cancers15020485.
57. Fansa S, Ghusn W, Tama E, et al. Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors. *Breast Cancer Res Treat*. 2024;208(3):553-563. doi:10.1007/s10549-024-07450-3

58. Vilarrasa N, San Jose P, Rubio MÁ, Lecube A. Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges. *Diabetes Metab Syndr Obes.* 2021;14:2807-2827. doi:10.2147/DMSO.S223618
59. Young V, Eiser C, Johnson B, et al. Eating problems in adolescents with Type 1 diabetes: a systematic review with meta-analysis. *Diabet Med.* 2013;30(2):189-198. doi:10.1111/j.1464-5491.2012.03771.x
60. Gitsi E, Livadas S, Angelopoulos N, Paparodis RD, Raftopoulou M, Argyrakopoulou G. A Nutritional Approach to Optimizing Pump Therapy in Type 1 Diabetes Mellitus. *Nutrients.* 2023;15(23):4897. doi:10.3390/nu15234897
61. Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. *Ann Pharmacother.* 2010;44(3):538-545. doi:10.1345/aph.1M210
62. Resnick O, Bril F, Beauchamp G. Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer? *Front Endocrinol.* 2025;15. doi:10.3389/fendo.2024.1520313
63. Rivera Gutierrez R, Tama E, Bechenati D, et al. Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity. *Mayo Clin Proc.* 2025;100(2):265-275. doi:10.1016/j.mayocp.2024.07.006
64. Do GLP-1 receptor agonists have a place in the treatment of people with type 1 diabetes? | *Medical Research Archives.* Accessed June 5, 2025. <https://esmed.org/MRA/mra/article/view/6110>
65. Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C. Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. *Diabetes Care.* 2022;45(3):650-658. doi:10.2337/dc21-1584
66. Edwards K, Li X, Lingvay I. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study. *J Clin Endocrinol Metab.* 2023;108(4):920-930. doi:10.1210/clinem/dgac618
67. Landau Z, Kowen-Sandbank G, Jakubowicz D, et al. Bariatric surgery in patients with type 1 diabetes: special considerations are warranted. *Ther Adv Endocrinol Metab.* 2019;10:2042018818822207. doi:10.1177/2042018818822207
68. Höskuldsdóttir G, Ekelund J, Miftaraj M, et al. Potential Benefits and Harms of Gastric Bypass Surgery in Obese Individuals With Type 1 Diabetes: A Nationwide, Matched, Observational Cohort Study. *Diabetes Care.* 2020;43(12):3079-3085. doi:10.2337/dc20-0388
69. Mahawar KK, De Alwis N, Carr WRJ, Jennings N, Schroeder N, Small PK. Bariatric Surgery in Type 1 Diabetes Mellitus: A Systematic Review. *Obes Surg.* 2016;26(1):196-204. doi:10.1007/s11695-015-1924-z
70. DeMik DE, Kohler JG, Carender CN, Glass NA, Brown TS, Bedard NA. What Is the Impact of Body Mass Index Cutoffs on Total Hip Arthroplasty Complications? *J Arthroplasty.* 2022;37(7):1320-1325.e1. doi:10.1016/j.arth.2022.03.004
71. Schmerler J, Hussain N, Kurian SJ, Khanuja HS, Oni JK, Hegde V. Preoperative weight loss before total hip arthroplasty negatively impacts postoperative outcomes. *Arthroplasty.* 2024;6(1):13. doi:10.1186/s42836-024-00237-3
72. Hameed D, Bains SS, Dubin JA, et al. Timing Matters: Optimizing the Timeframe for Preoperative Weight Loss to Mitigate Postoperative Infection Risks in Total Knee Arthroplasty. *J Arthroplasty.* 2024;39(6):1419-1423.e1. doi:10.1016/j.arth.2023.12.028
73. Kim BI, LaValva SM, Parks ML, Sculco PK, Della Valle AG, Lee GC. Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA. *J Bone Joint Surg Am.* 2025;107(4):348-355. doi:10.2106/JBJS.24.00468
74. Shul C, Hameed D, Oster B, et al. The Impact of Preoperative Weight Loss Timing on Surgical Outcomes in Total Hip Arthroplasty. *J Arthroplasty.* 2024;39(6):1424-1431. doi:10.1016/j.arth.2024.02.075

75. Rechenmacher AJ, Yancy WS, Bolognesi MP, Ryan SP, Jiranek WA, Horn ME. Does Medically Supervised Weight Loss Prior to Total Knee Arthroplasty Improve Patient-Reported Pain and Physical Function? *J Arthroplasty*. 2024;39(2):350-354. doi:10.1016/j.arth.2023.08.038
76. Ushakumari DS, Sladen RN. ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists. *Anesthesiology*. 2024;140(2):346. doi:10.1097/ALN.0000000000004776
77. Hashash JG, Thompson CC, Wang AY. AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication. *Clin Gastroenterol Hepatol*. 2024;22(4):705-707. doi:10.1016/j.cgh.2023.11.002
78. Kindel TL, Wang AY, Wadhwa A, et al. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. *Clin Gastroenterol Hepatol*. Published online October 29, 2024:S1542-3565(24)00910-8. doi:10.1016/j.cgh.2024.10.003
79. Alexander L, Christensen SM, Richardson L, et al. Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022. *Obes Pillars*. 2022;1:100005. doi:10.1016/j.obpill.2021.100005
80. Wilfahrt RP, Matthews AL. Treatment of Attention-Deficit/Hyperactivity Disorder in Outpatients With a History of Disordered Eating Symptoms. *Clin Neuropharmacol*. 2025;48(2):39-42. doi:10.1097/WNF.0000000000000626
81. Machado Cruz T. Clinical profiles in autism spectrum disorder: Enhancing diagnosis, treatment, and overall health outcomes. *Medicine Advances*. 2024;2(4):384-401. doi:10.1002/med4.89
82. Bowling A, Davison K, Haneuse S, Beardslee W, Miller DP. ADHD Medication, Dietary Patterns, Physical Activity, and BMI in Children: A Longitudinal Analysis of the ECLS-K Study. *Obesity (Silver Spring)*. 2017;25(10):1802-1808. doi:10.1002/oby.21949
83. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics*. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
84. Gurka MJ, Siddiqi SU, Filipp SL, et al. Attention deficit hyperactivity disorder medications and BMI trajectories: The role of medication type, sex and age. *Pediatr Obes*. 2021;16(4):e12738. doi:10.1111/ijpo.12738
85. Mansuri Z, Makani R, Trivedi C, et al. The role of metformin in treatment of weight gain associated with atypical antipsychotic treatment in children and adolescents: A systematic review and meta-analysis of randomized controlled trials. *Front Psychiatry*. 2022;13:933570. doi:10.3389/fpsyt.2022.933570
86. Puhl RM, Himmelstein MS, Pearl RL, Wojtanowski AC, Foster GD. Weight Stigma Among Sexual Minority Adults: Findings from a Matched Sample of Adults Engaged in Weight Management. *Obesity (Silver Spring)*. 2019;27(11):1906-1915. doi:10.1002/oby.22633
87. Convertino AD, Brady JP, Albright CA, Gonzales M, Blashill AJ. The role of sexual minority stress and community involvement on disordered eating, dysmorphic concerns and appearance- and performance-enhancing drug misuse. *Body Image*. 2021;36:53-63. doi:10.1016/j.bodyim.2020.10.006
88. Hanshaw BD, Goldhammer H, Wildgust M, Netanel S, Ben-Arieh A, Keuroghlian AS. A roadmap for engagement and inclusion of LGBTQIA+ people in clinical research. *Nat Med*. 2025;31(3):720-724. doi:10.1038/s41591-024-03471-z
89. Taormina JM, Iwamoto SJ. Filling a gap in care: addressing obesity in transgender and gender diverse patients. *Int J Obes (Lond)*. 2023;47(9):761-763. doi:10.1038/s41366-023-01334-0
90. van der Sluis WB, de Bruin RJM, Steensma TD, Bouman MB. Gender-affirmation surgery and bariatric surgery in transgender individuals in The Netherlands: Considerations, surgical techniques and outcomes. *Int J Transgend Health*. 2022;23(3):355-361. doi:10.1080/26895269.2021.1890302

91. Haymond MW, Araújo-Vilar D, Balseer J, et al. The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges. *Orphanet J Rare Dis.* 2023;18(1):127. doi:10.1186/s13023-023-02714-5
92. Oral EA, Gorden P, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. *Endocrine.* 2019;64(3):500-511. doi:10.1007/s12020-019-01862-8
93. Besci Ö, Firat SN, Özen S, et al. A National Multicenter Study of Leptin and Leptin Receptor Deficiency and Systematic Review. *J Clin Endocrinol Metab.* 2023;108(9):2371-2388. doi:10.1210/clinem/dgad099
94. Qamar S, Mallik R, Makaronidis J. Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction. *touchREV Endocrinol.* 2024;20(2):62-71. doi:10.17925/EE.2024.20.2.9
95. Miller J, Berry S, Ismail E. Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome. *Paediatr Drugs.* 2025;27(3):273-281. doi:10.1007/s40272-025-00681-x
96. Koceva A, Mlekuš Kozamernik K, Janež A, Herman R, Ferjan S, Jensterle M. Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review. *Front Endocrinol (Lausanne).* 2024;15:1528457. doi:10.3389/fendo.2024.1528457
97. Dinoi E, Daniele G, Michelucci A, et al. Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report. *Front Endocrinol (Lausanne).* 2025;16:1533209. doi:10.3389/fendo.2025.1533209
98. Kalinderi K, Goula V, Sapountzi E, Tsinopoulou VR, Fidani L. Syndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment. *Children (Basel).* 2024;11(2):153. doi:10.3390/children11020153
99. Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. *BMJ.* Published online April 10, 2024:e078225. doi:10.1136/bmj-2023-078225
100. Abi Zeid Daou C, Aboul Hosn O, Ghzayel L, Mourad M. Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database. *Endocrinol Diabetes Metab.* 2025;8(2):e70038. doi:10.1002/edm2.70038
101. Cordido M, Juiz-Valiña P, Urones P, Sangiao-Alvarelos S, Cordido F. Thyroid Function Alteration in Obesity and the Effect of Bariatric Surgery. *J Clin Med.* 2022;11(5):1340. doi:10.3390/jcm11051340
102. Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. *J Clin Endocrinol Metab.* 2005;90(1):124-127. doi:10.1210/jc.2004-1306
103. Medici BR, Nygaard B, la Cour JL, et al. Effects of levothyroxine substitution therapy on hunger and food intake in individuals with hypothyroidism. *Endocr Connect.* 2023;12(10):e230314. doi:10.1530/EC-23-0314
104. Karimifar M, Esmaili F, Salari A, Kachuei A, Faragzadegan Z, Karimifar M. Effects of Levothyroxine and thyroid stimulating hormone on bone loss in patients with primary hypothyroidism. *J Res Pharm Pract.* 2014;3(3):83-87. doi:10.4103/2279-042X.141099
105. Mohajer B, Moradi K, Guermazi A, et al. Levothyroxine use and longitudinal changes in thigh muscles in at-risk participants for knee osteoarthritis: preliminary analysis from Osteoarthritis Initiative cohort. *Arthritis Res Ther.* 2023;25(1):58. doi:10.1186/s13075-023-03012-y
106. Capuccio S, Scilletta S, La Rocca F, et al. Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels. *Biomolecules.* 2024;14(6):687. doi:10.3390/biom14060687

107. Roth CL, McCormack SE. Acquired hypothalamic obesity: A clinical overview and update. *Diabetes Obes Metab.* 2024;26 Suppl 2:34-45. doi:10.1111/dom.15530
108. Dimitri P, Roth CL. Treatment of Hypothalamic Obesity With GLP-1 Analogs. *J Endocr Soc.* 2024;9(1):bvae200. doi:10.1210/jendso/bvae200
109. Akinci B, Gular MC, Oral EA. Lipodystrophy Syndromes: Presentation and Treatment. In: Feingold KR, Ahmed SF, Anawalt B, et al., eds. *Endotext*. MDText.com, Inc.; 2000. Accessed June 7, 2025. <http://www.ncbi.nlm.nih.gov/books/NBK513130/>
110. Ten S, Bhangoo A, Buettner C. Tirzepatide for Congenital Generalized Lipodystrophy. *N Engl J Med.* 2025;392(7):717-719. doi:10.1056/NEJMc2413871
111. Brush M, Auh S, Cochran E, et al. Effects of Metreleptin in Patients With Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease. *J Clin Endocrinol Metab.* 2025;110(4):e1051-e1061. doi:10.1210/clinem/dgae335
112. Herbst KL, Kahn LA, Iker E, et al. Standard of care for lipedema in the United States. *Phlebology.* 2021;36(10):779-796. doi:10.1177/02683555211015887
113. Amato ACM, Amato JLS, Benitti DA. The Efficacy of Ketogenic Diets (Low Carbohydrate; High Fat) as a Potential Nutritional Intervention for Lipedema: A Systematic Review and Meta-Analysis. *Nutrients.* 2024;16(19):3276. doi:10.3390/nu16193276
114. Bejar-Chapa M, Rossi N, King N, Hussey MR, Winograd JM, Guastaldi FPS. Liposuction as a Treatment for Lipedema: A Scoping Review. *Plast Reconstr Surg Glob Open.* 2024;12(7):e5952. doi:10.1097/GOX.0000000000005952

3.6 Manage Weight-Related Conditions

1. American Diabetes Association Professional Practice Committee. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2025. *Diabetes Care.* 2025;48(1 Suppl 1):S86-S127. doi:10.2337/dc25-S005
2. Lingvay I, Cohen RV, Roux CWL, Sumithran P. Obesity in adults. *Lancet.* 2024;404(10456):972-987. doi:10.1016/S0140-6736(24)01210-8
3. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. *Circulation.* 2021;144(23):e472-e487. doi:10.1161/CIR.0000000000001031
4. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med.* 1997;336(16):1117-1124. doi:10.1056/NEJM199704173361601
5. Delgado-Lista J, Alcalá-Díaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet.* 2022;399(10338):1876-1885. doi:10.1016/S0140-6736(22)00122-2
6. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. *JAMA.* 2018;320(19):2020-2028. doi:10.1001/jama.2018.14854
7. Paluch AE, Boyer WR, Franklin BA, et al. Resistance Exercise Training in Individuals With and Without Cardiovascular Disease: 2023 Update: A Scientific Statement From the American Heart Association. *Circulation.* 2024;149(3):e217-e231. doi:10.1161/CIR.0000000000001189
8. U.S. Department of Agriculture and U.S. Department of Health and Human Services. *Dietary Guidelines for Americans, 2020-2025*. U.S. Government Printing Office; 2020. Accessed September 14, 2025. <https://www.dietaryguidelines.gov/>
9. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACC Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. *Circulation.* 2011;124(22):2458-2473. doi:10.1161/CIR.0b013e318235eb4d

10. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025. *Diabetes Care*. 2025;48(1 Suppl 1):S167-S180. doi:10.2337/dc25-S008
11. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med*. 2004;351(26):2683-2693. doi:10.1056/NEJMoa035622
12. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. *N Engl J Med*. 2017;376(7):641-651. doi:10.1056/NEJMoa1600869
13. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. *JAMA*. 2012;307(1):56-65. doi:10.1001/jama.2011.1914
14. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med*. 2007;357(8):741-752. doi:10.1056/NEJMoa066254
15. Riddle MC, Cefalu WT, Evans PH, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. *Diabetes Care*. Published online August 30, 2021. doi:10.2337/dci21-0034
16. Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). *Diabetes Care*. 2022;45(7):1574-1583. doi:10.2337/dc21-2441
17. Courcoulas AP, Patti ME, Hu B, et al. Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. *JAMA*. 2024;331(8):654-664. doi:10.1001/jama.2024.0318
18. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6):1269-1324. doi:10.1161/HYP.000000000000066
19. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140(10):e526-e622. doi:10.1161/1969.1.41313
20. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031
21. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol*. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538
22. Pallati PK, Shaligram A, Shostrom VK, Oleynikov D, McBride CL, Goede MR. Improvement in gastroesophageal reflux disease symptoms after various bariatric procedures: review of the Bariatric Outcomes Longitudinal Database. *Surg Obes Relat Dis*. 2014;10(3):502-507. doi:10.1016/j.soard.2014.02.002
23. Hudgel DW, Patel SR, Ahasic AM, et al. The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2018;198(6):e70-e87. doi:10.1164/rccm.201807-1326ST
24. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med*. 2012;8(5):597-619. Published 2012 Oct 15. doi:10.5664/jcsm.2172

25. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N Engl J Med*. 2024;391(13):1193-1205. doi:10.1056/NEJMoa2404881
26. Ma J, Strub P, Xiao L, et al. Behavioral weight loss and physical activity intervention in obese adults with asthma. A randomized trial. *Ann Am Thorac Soc*. 2015;12(1):1-11. doi:10.1513/AnnalsATS.201406-271OC
27. Nyenhuis SM, Kahwash B, Cooke A, Gregory KL, Greiwe J, Nanda A. Recommendations for Physical Activity in Asthma: A Work Group Report of the AAAAI Sports, Exercise, and Fitness Committee. *J Allergy Clin Immunol Pract*. 2022;10(2):433-443. doi:10.1016/j.jaip.2021.10.056
28. 2024 GINA Main Report. Global Initiative for Asthma - GINA. Accessed October 25, 2025. <https://ginasthma.org/2024-report/>
29. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241
30. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. *J Clin Endocrinol Metab*. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463
31. Moran LJ, Tassone EC, Boyle J, et al. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: Lifestyle management. *Obes Rev*. 2020;21(10):e13046. doi:10.1111/obr.13046
32. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. *JAMA*. 2018;320(19):2020-2028. doi:10.1001/jama.2018.14854
33. Duong V, Oo WM, Ding C, Culvenor AG, Hunter DJ. Evaluation and Treatment of Knee Pain: A Review. *JAMA*. 2023;330(16):1568-1580. doi:10.1001/jama.2023.19675
34. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. *JAMA*. 2013;310(12):1263-1273. doi:10.1001/jama.2013.277669
35. da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of nonsteroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet*. 2017;390(10090):e21-e33. doi:10.1016/S0140-6736(17)31744-0
36. Skou ST, Roos EM, Laursen MB, et al. A Randomized, Controlled Trial of Total Knee Replacement. *N Engl J Med*. 2015;373(17):1597-1606. doi:10.1056/NEJMoa1505467
37. Klimek M, Büchele G, Rehm M, et al. Long-Term Mortality of Patients With Osteoarthritis After Joint Replacement: Prognostic Value of Preoperative and Postoperative Pain and Function. *Arthritis Care Res (Hoboken)*. 2023;75(4):869-875. doi:10.1002/acr.24808
38. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Care Res (Hoboken)*. 2020;72(6):744-760. doi:10.1002/acr.24180
39. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. *Nutrients*. 2022;14(17):3525. Published 2022 Aug 26. doi:10.3390/nu14173525
40. Mondragon J, Klovenski V. Pseudotumor Cerebri. In: *StatPearls. Treasure Island (FL): StatPearls Publishing; September 29, 2022.*
41. Abbott S, Chan F, Tahrani AA, et al. Weight Management Interventions for Adults With Idiopathic Intracranial Hypertension. *Neurology*. 2023;101(21):e2138-e2150. doi:10.1212/WNL.0000000000207866

42. Christensen SM, Varney C, Gupta V, Wenz L, Bays HE. Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;4:100041. Published 2022 Nov 4. doi:10.1016/j.obpill.2022.100041
43. Tondt J, Bays HE. Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;2:100017. Published 2022 Apr 6. doi:10.1016/j.obpill.2022.100017
44. Herman BK, Deal LS, DiBenedetti DB, Nelson L, Fehnel SE, Brown TM. Development of the 7-Item Binge-Eating Disorder Screener (BEDS-7). *Prim Care Companion CNS Disord*. 2016;18(2). doi:10.4088/PCC.15m01896
45. Grilo CM, Juarascio A. Binge-Eating Disorder Interventions: Review, Current Status, and Implications. *Curr Obes Rep*. 2023;12(3):406-416. doi:10.1007/s13679-023-00517-0
46. Cortese S, Tessari L. Attention-Deficit/Hyperactivity Disorder (ADHD) and Obesity: Update 2016. *Curr Psychiatry Rep*. 2017;19(1):4. doi:10.1007/s11920-017-0754-1
47. Makin L, Zesch E, Meyer A, Mondelli V, Tchanturia K. Autism, ADHD, and Their Traits in Adults With Bulimia Nervosa and Binge Eating Disorder: A Scoping Review. *Eur Eat Disord Rev*. Published online January 26, 2025. doi:10.1002/erv.3177
48. Alexander L, Christensen SM, Richardson L, et al. Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022. *Obes Pillars*. 2022;1:100005. Published 2022 Jan 10. doi:10.1016/j.obpill.2021.100005

4

Professionalism



References

4.1 Maintain Professional Competence in Obesity Medicine

1. Obesity Medicine Association: Leaders in Obesity Medicine. Accessed October 25, 2025. <https://obesitymedicine.org/>
2. The Obesity Society - Research. Education. Action. Accessed October 25, 2025. <https://www.obesity.org/>
3. American Board of Obesity Medicine. February 11, 2016. Accessed October 25, 2025. <https://www.abom.org/>
4. Obesity Medicine Fellowship Council – OMFC. Accessed October 25, 2025. <https://omfellowship.org/>

4.2 Manage the Obesity Medicine Clinical Practice

1. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;1:100004. doi:10.1016/j.obpill.2021.100004.
2. Pennings N, Happel P, Hines S, et al. Obesity management in primary care: A joint clinical perspective and expert review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFPP). *Obes Pillars*. 2025;100042. doi:10.1016/j.obpill.2025.100042.
3. Laddu DR, Arena R, Bauman A, et al. Implementation of obesity science into clinical practice: A scientific statement from the American Heart Association. *Circulation*. 2024;149(14):e489-507. doi:10.1161/CIR.0000000000001221.
4. Holtrop JS, Connelly L, Nederveld A, et al. Models for delivering weight management in primary care: Qualitative results from the MOST Obesity Study. *J Am Board Fam Med*. 2023;36(4):603-13. doi:10.3122/jabfm.2022.220315R2.
5. Griauzde DH, Laiteerapong N, Kullgren JT, et al. A primary care-based weight navigation program and patient outcomes. *JAMA Netw Open*. 2024;7(6):e2418510. doi:10.1001/jamanetworkopen.2024.18510.
6. Ro S, Lackey K, Callender C, et al. Impact of a community-based, primary care weight management program: A practice-level evaluation. *Fam Med*. 2023;55(3):187-95. doi:10.22454/FamMed.2023.437163.
7. Wyse C, Case L, Walsh Ó, Shortall C, Jordan N, McCrea L, O'Malley G. Evaluating 12 years of implementing a multidisciplinary specialist child and adolescent obesity treatment service: patient-level outcomes. *Front Nutr*. 2022;9:895091. doi:10.3389/fnut.2022.895091.
8. Mayer J, Choi J, Jones DB, et al. Building a medical-surgical obesity center in an academic health system in West Virginia. *Obes Surg*. 2022;32(1):45-53. doi:10.1007/s11695-022-06531-2.

4.3 Reduce Weight Bias & Stigma

1. Fulton M, Dadana S, Srinivasan VN. Obesity, Stigma, and Discrimination (Archived). In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 26, 2023.
2. Westbury S, Oyebode O, van Rens T, Barber TM. Obesity Stigma: Causes, Consequences, and Potential Solutions. *Curr Obes Rep.* 2023;12(1):10-23. doi:10.1007/s13679-023-00495-3
3. Moizé V, Graham Y, Salas XR, Balcells M. Motivational Interviewing (MI) in Obesity Care: Cultivating Person-Centered and Supportive Clinical Conversations to Reduce Stigma: A Narrative Review. *Obesity Science & Practice.* 2025;11(1):e70057. doi:10.1002/osp4.70057
4. Phelan SM, Burgess DJ, Yeazel MW, Hellerstedt WL, Griffin JM, van Ryn M. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. *Obes Rev.* 2015;16(4):319-326. doi:10.1111/obr.12266
5. GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050. *Lancet.* 2024;404(10469):2278-2298. doi:10.1016/S0140-6736(24)01548-4
6. Brown CF, Zvenyach T, Paul E, Golden L, Varney C, Bays HE. Obesity and Advocacy: A Joint Clinical Perspective and Expert Review from the Obesity Medicine Association and the Obesity Action Coalition - 2024. *Obesity Pillars.* 2024;11:100119. doi:10.1016/j.obpill.2024.100119
7. Pennings N, Varney C, Hines S, et al. Obesity management in primary care: A joint clinical perspective and expert review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFPP) - 2025. *Obesity Pillars.* 2025;14:100172. doi:10.1016/j.obpill.2025.100172
8. Gudzone KA, Bennett WL, Cooper LA, Bleich SN. Patients who feel judged about their weight have lower trust in their primary care providers. *Patient Education and Counseling.* 2014;97(1):128-131. doi:10.1016/j.pec.2014.06.019
9. Pont SJ, Puhl R, Cook SR, Slusser W, SECTION ON OBESITY, THE OBESITY SOCIETY. Stigma Experienced by Children and Adolescents With Obesity. *Pediatrics.* 2017;140(6):e20173034. doi:10.1542/peds.2017-3034
10. Heitmann BL. The Impact of Novel Medications for Obesity on Weight Stigma and Societal Attitudes: A Narrative Review. *Curr Obes Rep.* 2025;14(1):18. doi:10.1007/s13679-025-00611-5
11. Pearl RL, Sheynblyum M. How Weight Bias and Stigma Undermine Healthcare Access and Utilization. *Curr Obes Rep.* 2025;14(1):11. doi:10.1007/s13679-025-00605-3
12. Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. *Am J Public Health.* 2010;100(6):1019-1028. doi:10.2105/AJPH.2009.159491

4.4 Advocate for Patients with Obesity within the Health System

1. Brown CF, Zvenyach T, Paul E, Golden L, Varney C, Bays HE. Obesity and Advocacy: A Joint Clinical Perspective and Expert Review from the Obesity Medicine Association and the Obesity Action Coalition - 2024. *Obesity Pillars.* 2024;11:100119. doi:10.1016/j.obpill.2024.100119
2. Neuman T, Corrado R, Banaag A, Koehlmoos TP. Utilization of antiobesity medications within the Military Health System. *Obesity (Silver Spring).* 2024;32(10):1825-1832. doi:10.1002/oby.24097
3. Zhang S, Manne S, Lin J, Yang J. Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States. *Obesity Science & Practice.* 2016;2(2):104-114. doi:10.1002/osp4.46

4. MacEwan J, Kan H, Chiu K, Poon JL, Shinde S, Ahmad NN. Antiobesity Medication Use Among Overweight and Obese Adults in the United States: 2015-2018. *Endocr Pract*. 2021;27(11):1139-1148. doi:10.1016/j.eprac.2021.07.004
5. Suissa K, Schneeweiss S, Kim DW, Patorno E. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. *Diabetes Obes Metab*. 2021;23(7):1542-1551. doi:10.1111/dom.14367
6. Gasoyan H, Tajeu G, Halpern MT, Sarwer DB. Reasons for Underutilization of Bariatric Surgery: The Role of Insurance Benefit Design. *Surg Obes Relat Dis*. 2019;15(1):146-151. doi:10.1016/j.soard.2018.10.005
7. Butsch WS, Robison K, Sharma R, Knecht J, Smolarz BG. Medicine Residents are Unprepared to Effectively Treat Patients with Obesity: Results from a U.S. Internal Medicine Residency Survey. *J Med Educ Curric Dev*. 2020;7:2382120520973206. doi:10.1177/2382120520973206
8. Butsch WS, Kushner RF, Alford S, Smolarz BG. Low priority of obesity education leads to lack of medical students' preparedness to effectively treat patients with obesity: results from the U.S. medical school obesity education curriculum benchmark study. *BMC Medical Education*. 2020;20(1):23. doi:10.1186/s12909-020-1925-z
9. Kushner RF, Horn DB, Butsch WS, et al. Development of Obesity Competencies for Medical Education: A Report from the Obesity Medicine Education Collaborative. *Obesity (Silver Spring)*. 2019;27(7):1063-1067. doi:10.1002/oby.22471

4.5 Raise Public Awareness of Obesity

1. Brown T, Moore TH, Hooper L, et al. Interventions for preventing obesity in children. *Cochrane Database Syst Rev*. 2019;7(7):CD001871. Published 2019 Jul 23. doi:10.1002/14651858.CD001871.pub4
2. Petersen R. Racial and Ethnic Disparities in Adult Obesity in the United States: CDC's Tracking to Inform State and Local Action. *Prev Chronic Dis*. 2019;16. doi:10.5888/pcd16.180579
3. Fulton M, Dadana S, Srinivasan VN. Obesity, Stigma, and Discrimination (Archived). In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; October 26, 2023.
4. The Four Pillars of Obesity Treatment | Obesity Medicine Association. Obesity Medicine Association. Accessed April 12, 2025. <https://obesitymedicine.org/about/four-pillars/>
5. Pennings N, Varney C, Hines S, et al. Obesity management in primary care: A joint clinical perspective and expert review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP) - 2025. *Obesity Pillars*. 2025;14:100172. doi:10.1016/j.obpill.2025.100172
6. Bray GA, Kim KK, Wilding JPH, on behalf of the World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obesity Reviews*. 2017;18(7):715-723. doi:10.1111/obr.12551
7. NCHS Data Brief, Number 508, September 2024. Accessed May 3, 2025. <https://www.cdc.gov/nchs/data/databriefs/db508.pdf>
8. CDC. Causes and Consequences of Childhood Obesity. Centers for Disease Control and Prevention. July 15, 2022. Accessed April 19, 2025. <https://www.cdc.gov/obesity/basics/consequences.html>
9. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. *Curr Obes Rep*. 2017;6(2):187-194. doi:10.1007/s13679-017-0262-y

10. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. *NCHS Data Brief*. 2017;(288):1-8.
11. Obesity and overweight. Accessed May 4, 2025. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
12. GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050. *Lancet*. 2024;404(10469):2278-2298. doi:10.1016/S0140-6736(24)01548-4
13. Phelan SM, Burgess DJ, Yeazel MW, Hellerstedt WL, Griffin JM, van Ryn M. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. *Obes Rev*. 2015;16(4):319-326. doi:10.1111/obr.12266
14. Goettler A, Grosse A, Sonntag D. Productivity loss due to overweight and obesity: a systematic review of indirect costs. *BMJ Open*. 2017;7(10):e014632. doi:10.1136/bmjopen-2016-014632
15. Swinburn BA, Kraak VI, Allender S, et al. The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report. *The Lancet*. 2019;393(10173):791-846. doi:10.1016/S0140-6736(18)32822-8
16. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N Engl J Med*. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301
17. Brown CF, Zvenyach T, Paul E, Golden L, Varney C, Bays HE. Obesity and Advocacy: A Joint Clinical Perspective and Expert Review from the Obesity Medicine Association and the Obesity Action Coalition - 2024. *Obesity Pillars*. 2024;11:100119. doi:10.1016/j.obpill.2024.100119